Processing 00000000.tx.1: Translational research in autoimmunity: aims of therapy in vasculitis Aims of Therapy/Series Editor: Lorraine Harper R. 

Phrase: "Translational research in autoimmunity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C3494163:Translational Research [Research Activity]
   770   C0035168:research [Research Activity]
   770   C0242481:Research [Research Activity]

Phrase: ":"

Phrase: "aims of therapy"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C1947946:Aims [Idea or Concept]
   790   C3540473:AIMS [Intellectual Product]
   756 E C2948600:Aim [Pharmacologic Substance]
   756 E C3540471:AIM [Gene or Genome]
   756 E C3540472:AIM [Functional Concept]

Phrase: "in vasculitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042384:Vasculitis [Disease or Syndrome]
  1000   C1963274:Vasculitis [Finding]

Phrase: "Aims of Therapy/Series Editor"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   760   C0039798:therapy [Functional Concept]
   760   C0087111:Therapy [Therapeutic or Preventive Procedure]
   760   C0205549:Series [Quantitative Concept]
   760   C1363945:Therapy [Finding]
   760   C1707883:Editor [Occupation or Discipline]
   760   C1947946:Aim [Idea or Concept]
   760   C2348044:Series [Intellectual Product]
   760   C2948600:Aim [Pharmacologic Substance]
   760   C3540471:AIM [Gene or Genome]
   760   C3540472:AIM [Functional Concept]
   760   C3540473:AIMS [Intellectual Product]

Phrase: ":"

Phrase: "Lorraine Harper R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205090:R- [Spatial Concept]
   827   C0684010:R. [Professional or Occupational Group]
   827   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.2: Watts, L. 

Phrase: "Watts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439261:Watt [Quantitative Concept]

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.3: Harper3, D. 

Phrase: "Harper3,"

Phrase: "D."
Processing 00000000.tx.4: Jayne4, J. 

Phrase: "Jayne4,"

Phrase: "J."
Processing 00000000.tx.5: Levy2, C. 

Phrase: "Levy2,"

Phrase: "C."
Processing 00000000.tx.6: Pusey2, C. 

Phrase: "Pusey2,"

Phrase: "C."
Processing 00000000.tx.7: Savage3, D. 

Phrase: "Savage3,"

Phrase: "D."
Processing 00000000.tx.8: G. 

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.9: I. 

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.10: Scott1 and J. 

Phrase: "Scott1"

Phrase: "and"

Phrase: "J."
Processing 00000000.tx.11: Williams3 Department of Rheumatology, Ipswich Hospital NHS Trust and School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, 1 Department of Rheumatology, Norfolk and Norwich University Hospital NHS Trust and School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, 2 Renal Section, Imperial College London, Hammersmith Hospitals NHS Trust, London, 3 Division of Immunity and Infection, Medical School, University of Birmingham, Birmingham and 4 Renal Medicine, Addenbrooke's Hospital, Cambridge, UK Correspondence to: R. 

Phrase: "Williams3 Department of Rheumatology,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C0587479:Rheumatology department [Health Care Related Organization]
   770   C1704729:Department [Organization]

Phrase: "Ipswich Hospital NHS Trust"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1273810:NHS Trust [Health Care Related Organization]
   812   C0237935:Trust [Individual Behavior]
   812   C3245466:trust [Idea or Concept]

Phrase: "and"

Phrase: "School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0036375:School [Manufactured Object,Organization]

Phrase: "Health Policy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018735:Health Policy [Regulation or Law]
   861   C0242456:Policy [Intellectual Product]

Phrase: "and"

Phrase: "Practice,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237607:practice [Mental Process]
  1000   C3245512:practice [Intellectual Product]

Phrase: "University of East Anglia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0041740:University [Manufactured Object,Organization]

Phrase: "Norwich,"

Phrase: "1 Department of Rheumatology,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C0587479:Rheumatology department [Health Care Related Organization]
   770   C1704729:Department [Organization]

Phrase: "Norfolk"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454866:Norfolk [Geographic Area]

Phrase: "and"

Phrase: "Norwich University Hospital NHS Trust"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   840   C1273810:NHS Trust [Health Care Related Organization]
   804   C0237935:Trust [Individual Behavior]
   804   C3245466:trust [Idea or Concept]

Phrase: "and"

Phrase: "School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0036375:School [Manufactured Object,Organization]

Phrase: "Health Policy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018735:Health Policy [Regulation or Law]
   861   C0242456:Policy [Intellectual Product]

Phrase: "and"

Phrase: "Practice,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237607:practice [Mental Process]
  1000   C3245512:practice [Intellectual Product]

Phrase: "University of East Anglia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0041740:University [Manufactured Object,Organization]

Phrase: "Norwich,"

Phrase: "2 Renal Section,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0205155:Section [Spatial Concept]
   827   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   827   C1522472:Section [Substance]
   827   C1552923:Section [Quantitative Concept]
   827   C1705191:Section [Physical Object]

Phrase: "Imperial College London,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0023973:London [Geographic Area]
   827   C0557806:College [Manufactured Object]

Phrase: "Hammersmith Hospitals NHS Trust,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1273810:NHS Trust [Health Care Related Organization]
   812   C0237935:Trust [Individual Behavior]
   812   C3245466:trust [Idea or Concept]

Phrase: "London,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023973:London [Geographic Area]

Phrase: "3 Division of Immunity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1293097:Division [Therapeutic or Preventive Procedure]
   770   C2919030:Division [Organization]
   770   C2919031:Division [Activity]

Phrase: "and"

Phrase: "Infection,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009450:Infection, NOS [Disease or Syndrome]
   928 E C0439663:Infected [Functional Concept]
   888 E C0030657:infectivity [Qualitative Concept]

Phrase: "Medical School,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036378:School, Medical [Health Care Related Organization,Manufactured Object]
   861   C0036375:School [Manufactured Object,Organization]

Phrase: "University of Birmingham,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Birmingham"

Phrase: "and"

Phrase: "4 Renal Medicine,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0027712:Renal medicine [Biomedical Occupation or Discipline]
   827   C0013227:Medicine, NOS [Pharmacologic Substance]
   827   C0025118:Medicine [Biomedical Occupation or Discipline]

Phrase: "Addenbrooke's Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   861   C1510665:Hospital [Qualitative Concept]
   777 E C1609061:Hospitals [Intellectual Product]

Phrase: "Cambridge,"

Phrase: "UK Correspondence to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0282413:Correspondence [Intellectual Product]

Phrase: ":"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.12: Watts, Department of Rheumatology, Ipswich Hospital NHS Trust, Heath Road, Ipswich IP4 5PD, UK. 

Phrase: "Watts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439261:Watt [Quantitative Concept]

Phrase: "Department of Rheumatology,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   858   C0587479:Rheumatology department [Health Care Related Organization]
   790   C1704729:Department [Organization]

Phrase: "Ipswich Hospital NHS Trust,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1273810:NHS Trust [Health Care Related Organization]
   812   C0237935:Trust [Individual Behavior]
   812   C3245466:trust [Idea or Concept]

Phrase: "Heath Road,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442650:Road [Manufactured Object]

Phrase: "Ipswich IP4 5PD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1553549:5pd [Medical Device]

Phrase: "UK."
Processing 00000000.tx.13: E-mail: Richard.watts{at}ipswichhospital.nhs.uk Despite significant advances in treatment, the systemic vasculitides remain something of an enigma as the aetiology remains obscure. 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "Richard.watts{at}ipswichhospital.nhs.uk Despite significant advances"

Phrase: "in treatment,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C0150312:In [Quantitative Concept]
   861   C0332285:In [Spatial Concept]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "the systemic vasculitides"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0264939:Vasculitides, Systemic [Finding]
   861   C0042384:Vasculitides [Disease or Syndrome]
   861   C0205373:Systemic [Functional Concept]
   827 E C1963274:Vasculitis [Finding]

Phrase: "remain"

Phrase: "something of an enigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1427812:ENIGMA [Gene or Genome]

Phrase: "as the aetiology"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:aetiology [Functional Concept]
  1000   C1314792:Aetiology [Functional Concept]
  1000   C1524003:Etiology [Conceptual Entity]

Phrase: "remains"

Phrase: "obscure."
Processing 00000000.tx.14: Five years ago a meeting VasculitisAims of Therapy was held in Cambridge to discuss the then state of the art in the management of vasculitis [1]. 

Phrase: "Five years ago"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439234:years [Temporal Concept]
   793 E C0439508:/year [Temporal Concept]

Phrase: "a meeting VasculitisAims of Therapy"

Phrase: "was"

Phrase: "held in Cambridge to"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C1948036:held [Idea or Concept]
   770   C2987518:hELD [Amino Acid, Peptide, or Protein]
   737 E C1553387:Hold [Idea or Concept]
   737 E C1948035:Hold [Activity]

Phrase: "discuss"

Phrase: "the then state of the art in the management of vasculitis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   738   C0003826:Art [Occupation or Discipline]
   738   C0220786:ART [Manufactured Object]
   738   C1301808:State [Geographic Area]
   738   C1442792:State [Functional Concept]
   738   C3148680:State [Geographic Area]

Phrase: "[1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "]."
Processing 00000000.tx.15: Since then there have been major advances in their treatment with the completion of the first wave of European Vasculitis Study Group (EUVAS) series of trials (NORAM, CYCAZREM and MEPEX) (see Table 1 for a summary). 

Phrase: "Since then there"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1711239:Since [Temporal Concept]
   827   C1883708:Then [Temporal Concept]

Phrase: "have"

Phrase: "been"

Phrase: "major advances in their treatment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C0725066:Advance [Medical Device]

Phrase: "with the completion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205197:Completion [Qualitative Concept]
  1000   C1554962:completion [Qualitative Concept]

Phrase: "of the first wave"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0678544:wave [Natural Phenomenon or Process]
   861   C1421479:WAVE [Gene or Genome]

Phrase: "of European Vasculitis Study Group (EUVAS) series"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0205549:Series [Quantitative Concept]
   804   C2348044:Series [Intellectual Product]

Phrase: "of trials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0008976:Trial [Research Activity]

Phrase: "(NORAM,"

Phrase: "CYCAZREM"

Phrase: "and"

Phrase: "MEPEX"

Phrase: ")"

Phrase: "("

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "Table 1 for a summary"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0039224:Table [Manufactured Object]
   760   C1552616:summary [Intellectual Product]
   760   C1706073:Table [Medical Device]
   760   C1706074:Table [Intellectual Product]
   760   C1706244:Summary [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.16: The results of these trials now provide a firm evidence base for the first line treatment of most patients presenting with systemic vasculitis. 

Phrase: "The results of these trials now"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "a firm evidence base for the first line treatment of most patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   736   C0002055:base [Inorganic Chemical]
   736   C0178499:Base [Chemical Viewed Functionally]
   736   C1880279:Base [Biomedical or Dental Material]
   734   C1709483:Patient Base [Quantitative Concept]

Phrase: "presenting with systemic vasculitis."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0264939:Systemic Vasculitis [Finding]
   770   C0042384:Vasculitis [Disease or Syndrome]
   770   C0205373:Systemic [Functional Concept]
   770   C0449450:Presenting [Idea or Concept]
   770   C1963274:Vasculitis [Finding]
   737 E C0150312:Present [Quantitative Concept]
Processing 00000000.tx.17: A major triumph has been the transformation of these diseases from conditions with an appalling prognosis to chronic relapsing and remitting diseases [2, 3]. 

Phrase: "A major triumph"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3643615:Triumph [Pharmacologic Substance]

Phrase: "has"

Phrase: "been"

Phrase: "the transformation of these diseases"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0040682:Transformation [Cell Function]
   760   C1510411:Transformation [Pathologic Function]
   760   C1705163:Transformation [Research Activity]

Phrase: "from conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   966   C0012634:condition [Disease or Syndrome]
   966   C0348080:Condition [Qualitative Concept]
   966   C1705253:Condition [Conceptual Entity]
   916 E C0009647:Conditioned [Mental Process]
   916 E C1701901:Conditional [Qualitative Concept]
   916 E C1963686:Conditional [Functional Concept]
   893 E C1519605:Conditionality [Conceptual Entity]

Phrase: "with an appalling prognosis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033325:Prognosis [Health Care Activity]

Phrase: "to chronic relapsing"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0035020:Relapsing [Phenomenon or Process]
   861   C0205336:relapsing [Temporal Concept]
   827 E C0277556:Relapse [Disease or Syndrome]

Phrase: "and"

Phrase: "remitting diseases"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Diseases [Disease or Syndrome]
   789 E C1836721:MALS [Finding]
   789 E C3538764:MALS [Gene or Genome]
   789 E C3540595:MAL [Gene or Genome]

Phrase: "[2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "]."
Processing 00000000.tx.18: View this table: [in this window] [in a new window]  TABLE 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.19: EUVAS trials in systemic vasculitis  In the first wave of EUVAS studies, The NORAM trial compared methotrexate (MTX) with cyclophosphamide (CYC) in 100 newly diagnosed patients with systemic ANCA-associated vasculitis (AAV), with serum creatinine <150 mol/l and no life- or organ-threatening involvement. 

Phrase: "EUVAS trials in systemic vasculitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0681815:study trials [Research Activity]
   711   C0008976:Trial [Research Activity]

Phrase: "In the first wave"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0678544:wave [Natural Phenomenon or Process]
   861   C1421479:WAVE [Gene or Genome]

Phrase: "of EUVAS studies,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0947630:studies [Laboratory Procedure]

Phrase: "The NORAM trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0008976:Trial [Research Activity]

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "methotrexate (MTX) with cyclophosphamide (CYC)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   858   C0281491:cyclophosphamide/methotrexate [Therapeutic or Preventive Procedure]
   790   C0025677:Methotrexate [Organic Chemical,Pharmacologic Substance]

Phrase: "in 100 newly diagnosed patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "with systemic ANCA-associated vasculitis (AAV),"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   923   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   902   C0264939:Systemic Vasculitis [Finding]
   812   C0042384:Vasculitis [Disease or Syndrome]
   812   C0103647:ANCA [Immunologic Factor]
   812   C0332281:Associated [Qualitative Concept]
   812   C1963274:Vasculitis [Finding]
   779 E C0750490:Associate [Idea or Concept]
   779 E C1706221:Associate [Professional or Occupational Group]

Phrase: "with serum creatinine"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0201976:Serum creatinine [Laboratory Procedure]
  1000   C0600061:serum creatinine [Laboratory or Test Result]
   861   C0010294:Creatinine [Biologically Active Substance,Organic Chemical]
   861   C0229671:Serum [Body Substance]
   861   C1546774:Serum [Intellectual Product]
   861   C1550100:Serum [Body Substance]
   861   C1561535:Creatinine [Finding]

Phrase: "<150 mol/l"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   901   C0347982:mol/L [Quantitative Concept]

Phrase: "and"

Phrase: "no life-"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0376558:Life [Idea or Concept]
   916 E C0595998:lives [Finding]

Phrase: "or"

Phrase: "organ-threatening involvement."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1314939:Involvement [Functional Concept]
Processing 00000000.tx.20: At the primary endpoint (remission at 6 months), equal numbers of patients were in remission (MTX 89.8% vs CYC 93.5%). 

Phrase: "At the primary endpoint"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C2986535:Primary Endpoint [Indicator, Reagent, or Diagnostic Aid]
   861   C2349179:End Point [Qualitative Concept]
   861   C2826544:ENDPOINT [Quantitative Concept]

Phrase: "(remission at 6 months"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0544452:Remission [Finding]
   770   C0687702:remission [Neoplastic Process]

Phrase: ")"

Phrase: ","

Phrase: "equal numbers of patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   909   C2360800:Number of patients [Finding]
   802   C1830427:Patient number [Intellectual Product]
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "were in remission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0544452:Remission [Finding]
   790   C0687702:remission [Neoplastic Process]

Phrase: "(MTX 89.8%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0025677:Methotrexate [Organic Chemical,Pharmacologic Substance]

Phrase: "vs"

Phrase: "CYC 93.5%"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   771 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   771 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.21: The relapse rate after 1 yr (when the trial medications stopped) was unacceptably high (69.5% MTX and 45% CYC). 

Phrase: "The relapse rate after 1 yr ("
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0035020:Relapse [Phenomenon or Process]
   753   C0205336:relapse [Temporal Concept]
   753   C0277556:Relapse [Disease or Syndrome]
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]

Phrase: "when"

Phrase: "the trial medications"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0013227:Medications [Pharmacologic Substance]
   861   C0802604:Medications [Clinical Attribute]
   861   C2598133:Medications [Clinical Attribute]
   827 E C3244316:medication [Functional Concept]

Phrase: "stopped"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1272691:stopped [Qualitative Concept]
   966 E C1947925:Stop [Activity]
   966 E C2746065:Stop [Temporal Concept]

Phrase: ")"

Phrase: "was"

Phrase: "unacceptably high"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205250:High [Qualitative Concept]
   861   C1299351:High [Qualitative Concept]
   861   C2700149:HIGH [Intellectual Product]

Phrase: "(69.5% MTX"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0025677:Methotrexate [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "45% CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.22: Mean time to relapse was 13.5 months, suggesting that even in non-renal AAV therapy should not be rapidly tapered [4]. 

Phrase: "Mean time to"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0040223:Time [Temporal Concept]
   827   C3541383:Time [Temporal Concept]
   771 E C0442043:Temporal [Spatial Concept]
   771 E C2362314:Temporal [Temporal Concept]
   743 E C1632851:Times [Quantitative Concept]

Phrase: "relapse"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035020:Relapse [Phenomenon or Process]
  1000   C0205336:relapse [Temporal Concept]
  1000   C0277556:Relapse [Disease or Syndrome]

Phrase: "was"

Phrase: "13.5 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that even in non-renal AAV therapy"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   767   C0152002:Renal vasculitis [Disease or Syndrome]
   744   C0022646:Renal [Body Part, Organ, or Organ Component]
   744   C0039798:therapy [Functional Concept]
   744   C0042384:Vasculitis [Disease or Syndrome]
   744   C0087111:Therapy [Therapeutic or Preventive Procedure]
   744   C0332281:Associated [Qualitative Concept]
   744   C1363945:Therapy [Finding]
   744   C1518422:Non [Functional Concept]
   744   C1963274:Vasculitis [Finding]
   711 E C0750490:Associate [Idea or Concept]
   711 E C1706221:Associate [Professional or Occupational Group]

Phrase: "should"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "rapidly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1637379:Rapidly [Qualitative Concept]

Phrase: "tapered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441640:tapered [Health Care Activity]

Phrase: "[4"

Phrase: "]."
Processing 00000000.tx.23: The CYCAZAREM trial compared azathioprine (AZA) and CYC for maintenance of remission in patients with moderate renal involvement (creatinine <500 mol/l) [5]. 

Phrase: "The CYCAZAREM trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0008976:Trial [Research Activity]

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "azathioprine (AZA)"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0004482:Azathioprine [Organic Chemical,Pharmacologic Substance]
   944 E C0699279:Imuran [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "CYC for maintenance of remission"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   760   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   704 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   704 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with moderate renal involvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1314939:Involvement [Functional Concept]

Phrase: "(creatinine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0010294:Creatinine [Biologically Active Substance,Organic Chemical]
  1000   C1561535:Creatinine [Finding]

Phrase: "<500 mol/l) [5"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   861   C0347982:mol/L [Quantitative Concept]
   812   C0027960:Mole [Neoplastic Process]
   812   C0324740:Mole [Mammal]
   812   C0439189:Mole [Quantitative Concept]
   812   C1456781:mole [Neoplastic Process]
   812   C1824986:mol [Gene or Genome]
   729 E C0026367:Molar [Body Part, Organ, or Organ Component]
   712 E C0027962:moles [Neoplastic Process]

Phrase: "]."
Processing 00000000.tx.24: One hundred and fifty-five patients with AAV were studied. 

Phrase: "One"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "hundred"

Phrase: "and"

Phrase: "fifty-five patients with AAV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "studied."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]
Processing 00000000.tx.25: Oral CYC (2 mg/kg/day) and prednisolone (1 mg/kg/day tapering to 0.25 mg/kg/day by 12 weeks) resulted in remission in 144 patients. 

Phrase: "Oral CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "(2 mg/kg/day"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0439400:mg/kg/day [Quantitative Concept]
   875   C0439422:mg day [Quantitative Concept]
   875   C0439423:mg/day [Quantitative Concept]
   861   C0439418:kg/day [Quantitative Concept]
   812   C0332173:/day [Temporal Concept]
   812   C0439228:day [Temporal Concept]
   812   C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: "and"

Phrase: "prednisolone"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0032950:prednisolone [Pharmacologic Substance,Steroid]
   944 E C0699535:Delta- Cortef [Pharmacologic Substance,Steroid]
   944 E C0699538:Sterane [Pharmacologic Substance,Steroid]
   944 E C0701477:Meticortelone [Pharmacologic Substance,Steroid]
   944 E C0702183:Hydeltra [Pharmacologic Substance,Steroid]

Phrase: "(1 mg/kg/day tapering"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0441640:Tapering [Health Care Activity]
   804   C1548969:Tapering [Idea or Concept]
   717   C0439400:mg/kg/day [Quantitative Concept]
   708   C1442449:1 Day [Temporal Concept]

Phrase: "to 0.25 mg/kg/day"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   884   C0439400:mg/kg/day [Quantitative Concept]
   853   C0439422:mg day [Quantitative Concept]
   853   C0439423:mg/day [Quantitative Concept]
   840   C0439418:kg/day [Quantitative Concept]
   804   C0332173:/day [Temporal Concept]
   804   C0439228:day [Temporal Concept]
   804   C0439505:/day [Temporal Concept]

Phrase: "by 12 weeks"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]

Phrase: ")"

Phrase: "resulted in remission"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0544452:Remission [Finding]
   790   C0687702:remission [Neoplastic Process]
   756   C1274040:Result [Functional Concept]
   756   C1546471:Result [Idea or Concept]
   756   C2825142:Result [Finding]

Phrase: "in 144 patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.26: One hundred and nineteen (77%) achieved remission by 3 months. 

Phrase: "One"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "hundred"

Phrase: "and"

Phrase: "nineteen"

Phrase: "(77%"

Phrase: ")"

Phrase: "achieved remission by 3 months."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0544452:Remission [Finding]
   760   C0687702:remission [Neoplastic Process]
Processing 00000000.tx.27: There were seven deaths during the induction phase and one withdrawal. 

Phrase: "There"

Phrase: "were"

Phrase: "seven deaths during the induction phase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0011065:deaths [Organism Function]
   753   C1306577:DEATHS [Finding]

Phrase: "and"

Phrase: "one withdrawal."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2349954:Withdrawal [Activity]
   861   C2825032:Withdrawal [Mental or Behavioral Dysfunction]
Processing 00000000.tx.28: After remission induction at 36 months, patients were randomized to either continue CYC (1.5 mg/kg/day) for 12 months or switch to AZA (2 mg/kg/day), with the same prednisolone dose (10 mg/day). 

Phrase: "After remission induction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035052:Remission Induction [Therapeutic or Preventive Procedure]
   861   C0205263:Induction [Functional Concept]
   861   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "at 36 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "randomized to either"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0034656:randomized [Research Activity]

Phrase: "continue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continue [Idea or Concept]

Phrase: "CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "(1.5 mg/kg/day"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   897   C1442449:1 Day [Temporal Concept]
   884   C0439400:mg/kg/day [Quantitative Concept]
   853   C0439422:mg day [Quantitative Concept]
   853   C0439423:mg/day [Quantitative Concept]
   840   C0439418:kg/day [Quantitative Concept]
   804   C0332173:/day [Temporal Concept]
   804   C0439228:day [Temporal Concept]
   804   C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: "for 12 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "or"

Phrase: "switch to AZA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707719:Switch [Manufactured Object]

Phrase: "(2 mg/kg/day"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0439400:mg/kg/day [Quantitative Concept]
   875   C0439422:mg day [Quantitative Concept]
   875   C0439423:mg/day [Quantitative Concept]
   861   C0439418:kg/day [Quantitative Concept]
   812   C0332173:/day [Temporal Concept]
   812   C0439228:day [Temporal Concept]
   812   C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: ","

Phrase: "with the same prednisolone dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0178602:Dose [Quantitative Concept]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]

Phrase: "(10 mg/day"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0439422:mg day [Quantitative Concept]
   901   C0439423:mg/day [Quantitative Concept]
   827   C0332173:/day [Temporal Concept]
   827   C0439228:day [Temporal Concept]
   827   C0439505:/day [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.29: At 12 months both groups received AZA (1.5 mg/kg/day) and prednisolone (7.5 mg/day). 

Phrase: "At 12 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "both"

Phrase: "groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0441833:Group [Idea or Concept]
  1000   C0687744:group [Population Group]
  1000   C1257890:Group [Population Group]
  1000   C1552516:Group [Health Care Related Organization]
  1000   C1552839:groups [Idea or Concept]
  1000   C1705428:Group [Conceptual Entity]
  1000   C1705429:Group [Population Group]

Phrase: "received AZA"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0004482:Azathioprine [Organic Chemical,Pharmacologic Substance]
   805 E C0699279:Imuran [Organic Chemical,Pharmacologic Substance]

Phrase: "(1.5 mg/kg/day"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   897   C1442449:1 Day [Temporal Concept]
   884   C0439400:mg/kg/day [Quantitative Concept]
   853   C0439422:mg day [Quantitative Concept]
   853   C0439423:mg/day [Quantitative Concept]
   840   C0439418:kg/day [Quantitative Concept]
   804   C0332173:/day [Temporal Concept]
   804   C0439228:day [Temporal Concept]
   804   C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: "and"

Phrase: "prednisolone"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0032950:prednisolone [Pharmacologic Substance,Steroid]
   944 E C0699535:Delta- Cortef [Pharmacologic Substance,Steroid]
   944 E C0699538:Sterane [Pharmacologic Substance,Steroid]
   944 E C0701477:Meticortelone [Pharmacologic Substance,Steroid]
   944 E C0702183:Hydeltra [Pharmacologic Substance,Steroid]

Phrase: "(7.5 mg/day"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0439422:mg day [Quantitative Concept]
   861   C0439423:mg/day [Quantitative Concept]
   812   C0332173:/day [Temporal Concept]
   812   C0439228:day [Temporal Concept]
   812   C0439505:/day [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.30: There was no difference in relapse rates (15.5% in the AZA group and 13.7% in the CYC group) [P = 0.65; 95% confidence interval (CI) 9.9 to +13.0%] up to the end of the study at 18 months after treatment outset. 

Phrase: "There"

Phrase: "was"

Phrase: "no difference in relapse rates"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1705241:*Difference [Quantitative Concept]
   760   C1705242:Difference [Qualitative Concept]

Phrase: "(15.5% in the AZA group"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0004482:Azathioprine [Organic Chemical,Pharmacologic Substance]
   753   C0441833:Group [Idea or Concept]
   753   C0687744:group [Population Group]
   753   C1257890:Group [Population Group]
   753   C1552516:Group [Health Care Related Organization]
   753   C1705428:Group [Conceptual Entity]
   753   C1705429:Group [Population Group]

Phrase: "and"

Phrase: "13.7% in the CYC group"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   753   C0441833:Group [Idea or Concept]
   753   C0687744:group [Population Group]
   753   C1257890:Group [Population Group]
   753   C1552516:Group [Health Care Related Organization]
   753   C1705428:Group [Conceptual Entity]
   753   C1705429:Group [Population Group]

Phrase: ")"

Phrase: "[P = 0.65"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0450385:65 [Intellectual Product]
   827   C2603361:P' [Clinical Attribute]

Phrase: "; 95% confidence interval (CI) 9.9 to +13.0%"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   812   C0009667:Confidence Interval [Quantitative Concept]
   793   C0237529:Confidence [Mental Process]
   793   C1272706:Interval [Temporal Concept]
   793   C1552654:Interval [Idea or Concept]
   793   C1552713:Interval [Intellectual Product]
   793   C1704725:Confidence [Qualitative Concept]
   793   C1704726:Confidence [Mental Process]
   721 E C0558095:Confident [Individual Behavior]

Phrase: "]"

Phrase: "up to the end"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "of the study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "at 18 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "after treatment outset."
Processing 00000000.tx.31: This suggests that CYC can be safely withdrawn following induction of remission. 

Phrase: "This"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "can"

Phrase: "be"

Phrase: "safely"

Phrase: "withdrawn"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0424092:Withdrawn [Finding]
  1000   C2349954:Withdrawn [Activity]
  1000   C2825032:Withdrawn [Mental or Behavioral Dysfunction]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "induction of remission."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0035052:Induction of Remission [Therapeutic or Preventive Procedure]
           Remission Induction
   790   C0205263:Induction [Functional Concept]
   790   C0857127:induction [Therapeutic or Preventive Procedure]
Processing 00000000.tx.32: The MEPEX trial compared plasma exchange and pulsed methylprednisolone as adjunctive therapy in biopsy-proven AAV with acute renal failure (creatinine >500 mol/l) [abstract, 6]. 

Phrase: "The MEPEX trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0008976:Trial [Research Activity]

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "plasma exchange"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0032113:Plasma Exchange [Therapeutic or Preventive Procedure]
  1000   C0032134:Plasma Exchange [Therapeutic or Preventive Procedure]
   861   C0032105:Plasma [Body Substance]
   861   C0678640:exchange [Social Behavior]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "and"

Phrase: "pulsed methylprednisolone as adjunctive therapy"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   824   C0587279:Methylprednisolone pulse therapy [Therapeutic or Preventive Procedure]
   760   C0025815:Methylprednisolone [Hormone,Pharmacologic Substance,Steroid]
   704 E C0699458:Medrol [Pharmacologic Substance,Steroid]

Phrase: "in biopsy-proven AAV"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0042384:Vasculitis [Disease or Syndrome]
   812   C1963274:Vasculitis [Finding]

Phrase: "with acute renal failure"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0022660:Acute Renal Failure [Disease or Syndrome]
   913   C0231176:Acute failure [Pathologic Function]
   901   C0035078:Renal Failure [Disease or Syndrome]
   901   C1963154:Renal failure [Finding]
   827   C0022646:Renal [Body Part, Organ, or Organ Component]
   827   C0205178:acute [Temporal Concept]
   827   C0231174:Failure [Functional Concept]
   827   C0680095:failure [Individual Behavior]

Phrase: "(creatinine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0010294:Creatinine [Biologically Active Substance,Organic Chemical]
  1000   C1561535:Creatinine [Finding]

Phrase: ">500 mol/l) [abstract,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0000857:Abstract [Occupational Activity]
   812   C0600678:Abstract [Intellectual Product]
   812   C1552863:Abstract [Idea or Concept]

Phrase: "6"

Phrase: "]."
Processing 00000000.tx.33: One hundred and fifty-one patients received either seven plasma exchanges (60 ml/kg) or three pulses of methylprednisolone (15 mg/kg) in addition to standard therapy with cyclophosphamide and tapering prednisolone. 

Phrase: "One"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "hundred"

Phrase: "and"

Phrase: "fifty-one patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "either seven plasma exchanges"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0032113:Plasma Exchanges [Therapeutic or Preventive Procedure]
   827 E C0032134:Plasma Exchange [Therapeutic or Preventive Procedure]
   812   C0032105:Plasma [Body Substance]
   812   C0678640:exchanges [Social Behavior]
   812   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "(60 ml/kg)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1300574:mL/kg [Quantitative Concept]
   827   C0022718:KG [Geographic Area]
   827   C0439209:kg [Quantitative Concept]

Phrase: "or"

Phrase: "three pulses of methylprednisolone"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0034107:Pulses [Health Care Activity]
   770   C0391850:PULSES [Physiologic Function]
   737 E C0232117:PULSE [Clinical Attribute]
   737 E C1947910:Pulse [Phenomenon or Process]

Phrase: "(15 mg/kg"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0439272:mg kg [Quantitative Concept]
   827   C0022718:KG [Geographic Area]
   827   C0439209:kg [Quantitative Concept]
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: ")"

Phrase: "in addition to standard therapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C2936643:standard therapy [Therapeutic or Preventive Procedure]
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "with cyclophosphamide"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "and"

Phrase: "tapering prednisolone."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0032950:prednisolone [Pharmacologic Substance,Steroid]
   805 E C0699535:Delta- Cortef [Pharmacologic Substance,Steroid]
   805 E C0699538:Sterane [Pharmacologic Substance,Steroid]
   805 E C0701477:Meticortelone [Pharmacologic Substance,Steroid]
   805 E C0702183:Hydeltra [Pharmacologic Substance,Steroid]
Processing 00000000.tx.34: Preliminary data suggest that renal outcome was better in the plasma exchange-treated group, when expressed as either dialysis independence in surviving patients or overall rate of dialysis-free survival. 

Phrase: "Preliminary data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that renal outcome"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1274040:Outcome [Functional Concept]

Phrase: "was"

Phrase: "better in the plasma exchange-treated group,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0332272:Better [Qualitative Concept]

Phrase: "when"

Phrase: "expressed as either dialysis independence"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0011945:Dialysis [Natural Phenomenon or Process]
   760   C0011946:dialysis [Therapeutic or Preventive Procedure]
   760   C0085862:Independence [Idea or Concept]
   760   C0917873:dialysis [Therapeutic or Preventive Procedure]
   760   C1059964:Dialysis [Eukaryote]

Phrase: "in surviving patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "or"

Phrase: "overall rate of dialysis-free survival."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   814   C0038954:overall survival rate [Quantitative Concept]
           Survival Rate
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]
Processing 00000000.tx.35: Death rates were similar in the two groups. 

Phrase: "Death rates"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0205848:Rates, Death [Quantitative Concept]
   966 E C0026565:Death rate [Quantitative Concept]
   966 E C1108678:death rate [Quantitative Concept]
   861   C0011065:Death [Organism Function]
   861   C1306577:Death, NOS [Finding]
   827   C0871208:Rate [Activity]
   827   C1521828:Rate [Quantitative Concept]

Phrase: "were"

Phrase: "similar in the two groups."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2348205:Similar [Qualitative Concept]
Processing 00000000.tx.36: These results were maintained at the 1-yr follow-up. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "were"

Phrase: "maintained at the 1-yr"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0439234:yr [Temporal Concept]
   760   C1314677:Maintained [Functional Concept]
   726 E C0024501:Maintain [Activity]

Phrase: "follow-up."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0589120:Follow-up [Finding]
  1000   C1522577:follow-up [Health Care Activity]
  1000   C1704685:FOLLOW-UP [Intellectual Product]
  1000   C3274571:FOLLOW-UP [Health Care Activity]
   861   C0332283:follow [Temporal Concept]
   861   C1719822:Follow [Intellectual Product]
Processing 00000000.tx.37: Recruitment is now complete and data analysis is taking place. 

Phrase: "Recruitment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2949735:Recruitment [Activity]

Phrase: "is"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "complete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Complete [Qualitative Concept]

Phrase: "and"

Phrase: "data analysis"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0010992:Data Analysis [Occupational Activity]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1511726:Data [Idea or Concept]
   861   C1524024:analysis [Functional Concept]
   861   C3245479:data [Medical Device]

Phrase: "is"

Phrase: "taking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1515187:Take [Health Care Activity]

Phrase: "place."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0442504:Place [Spatial Concept]
  1000   C1704765:Place [Functional Concept]
  1000   C1882509:Place [Activity]
  1000   C3496241:place [Disease or Syndrome]
Processing 00000000.tx.38: The second wave of studies started about 5 yr ago and is now nearing completion. 

Phrase: "The second wave of studies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0678544:wave [Natural Phenomenon or Process]
   760   C1421479:WAVE [Gene or Genome]

Phrase: "started about 5 yr ago"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0439234:yr [Temporal Concept]
   760   C1272689:Started [Qualitative Concept]
   726 E C0439659:Start [Temporal Concept]

Phrase: "and"

Phrase: "is"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "nearing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0475806:Near [Finding]
   966   C1706276:Near [Qualitative Concept]

Phrase: "completion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205197:Completion [Qualitative Concept]
  1000   C1554962:completion [Qualitative Concept]
Processing 00000000.tx.39: CYCLOPS was designed to address the question whether pulse CYC was as effective as and less toxic than conventional oral low-dose daily CYC. 

Phrase: "CYCLOPS"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0266667:Cyclops [Congenital Abnormality]
  1000   C0323854:Cyclops [Eukaryote]

Phrase: "was"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "address"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376649:Address [Intellectual Product]
  1000   C1442065:Address [Spatial Concept]

Phrase: "the question"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522634:Question [Intellectual Product]

Phrase: "whether"

Phrase: "pulse CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "was"

Phrase: "as"

Phrase: "effective as"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1280519:effective [Qualitative Concept]
   833   C1704419:Effective [Qualitative Concept]

Phrase: "and"

Phrase: "less toxic than conventional oral low-dose daily CYC."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0600688:toxic [Injury or Poisoning]
   742   C1407029:Toxic [Qualitative Concept]
Processing 00000000.tx.40: A meta-analysis of 143 patients in three randomized controlled trials of ANCA-associated vasculitis concluded that pulsed CYC was less likely to fail to induce remission than continuous oral CYC and had a significantly lower risk of infection and leucopenia [7]. 

Phrase: "A meta-analysis of 143 patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0282458:Meta-Analysis [Intellectual Product]
   790   C0920317:Meta-Analysis [Research Activity]
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1042496:Meta [Eukaryote]
   753   C1524024:analysis [Functional Concept]

Phrase: "in three randomized controlled trials"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   923   C0282440:RANDOMIZED CONTROLLED TRIALS [Intellectual Product,Research Activity]
   890 E C1096777:Randomized Controlled Trial [Intellectual Product,Research Activity]
   812   C0034656:randomized [Research Activity]
   812   C2587213:Controlled [Functional Concept]
   779   C0008976:Trial [Research Activity]
   779 E C0243148:control [Qualitative Concept]
   779 E C1550141:Control [Substance]
   779 E C1882979:Control [Conceptual Entity]
   779 E C3274648:Control [Qualitative Concept]

Phrase: "of ANCA-associated vasculitis"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   827   C0042384:Vasculitis [Disease or Syndrome]
   827   C0103647:ANCA [Immunologic Factor]
   827   C0332281:Associated [Qualitative Concept]
   827   C1963274:Vasculitis [Finding]
   793 E C0750490:Associate [Idea or Concept]
   793 E C1706221:Associate [Professional or Occupational Group]

Phrase: "concluded"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that pulsed CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "was"

Phrase: "less likely to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0332148:Likely [Qualitative Concept]
   827   C0439092:less [Intellectual Product]
   827   C0547044:Less [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]

Phrase: "fail"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:fail [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "remission than continuous oral CYC"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0544452:Remission [Finding]
   760   C0687702:remission [Neoplastic Process]

Phrase: "and"

Phrase: "had"

Phrase: "a significantly lower risk of infection"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   783   C0582147:Infection risk [Finding]
   773   C3272281:Low Risk [Finding]
   773   C3538919:Low Risk [Quantitative Concept]
   753   C0035647:Risk [Qualitative Concept]
   753   C0441994:Lower [Spatial Concept]
   753   C1548802:Lower [Body Location or Region]
   753   C2003888:Lower [Activity]
   719 E C0205251:low [Qualitative Concept]
   719 E C1299352:Low [Qualitative Concept]
   719 E C1550472:low [Idea or Concept]

Phrase: "and"

Phrase: "leucopenia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023530:Leucopenia [Disease or Syndrome]

Phrase: "[7"

Phrase: "]."
Processing 00000000.tx.41: Relapses occurred slightly more frequently with pulsed CYC treatment. 

Phrase: "Relapses"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0035020:Relapses [Phenomenon or Process]
   966 E C0205336:relapse [Temporal Concept]
   966 E C0277556:Relapse [Disease or Syndrome]

Phrase: "occurred"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1709305:Occurred [Activity]
   966 E C2745955:OCCUR [Temporal Concept]

Phrase: "slightly more frequently with pulsed CYC treatment."
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   748   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   748   C0039798:treatment [Functional Concept]
   748   C0087111:Treatment [Therapeutic or Preventive Procedure]
   748   C0332183:Frequently [Temporal Concept]
   748   C0750482:Slightly [Idea or Concept]
   748   C1522326:Treatment [Functional Concept]
   748   C1533734:Treatment [Therapeutic or Preventive Procedure]
   748   C1705169:Treatment [Conceptual Entity]
   748   C1947910:Pulsed [Phenomenon or Process]
   748   C3538994:TREATMENT [Research Activity]
   714 E C0232117:PULSE [Clinical Attribute]
   714 E C0391850:Pulse [Physiologic Function]
Processing 00000000.tx.42: The 11 non-randomized studies comprised 202 patients receiving pulse CYC. 

Phrase: "The 11 non-randomized studies"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   812   C0034656:randomized [Research Activity]
   812   C0947630:studies [Laboratory Procedure]
   812   C1518422:Non [Functional Concept]
   779 E C0557651:Study [Manufactured Object]
   779 E C2603343:Study [Research Activity]

Phrase: "comprised"

Phrase: "202 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "pulse CYC."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   805 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]
Processing 00000000.tx.43: Pulses of CYC were given at doses of 3751000 mg/m2 per pulse at 1- to 4-week intervals with variable steroid and adjuvant therapy regimens. 

Phrase: "Pulses of CYC"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0034107:Pulses [Health Care Activity]
   790   C0391850:PULSES [Physiologic Function]
   756 E C0232117:PULSE [Clinical Attribute]
   756 E C1947910:Pulse [Phenomenon or Process]

Phrase: "were"

Phrase: "given at doses of 3751000 mg/m2"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   778   C1319266:mg/m2 [Quantitative Concept]
   748   C0178602:Doses [Quantitative Concept]
   748   C0439269:mg% [Quantitative Concept]
   748   C0457242:m2 [Quantitative Concept]
   748   C1442162:GIVEN [Conceptual Entity]
   748   C1550718:given [Idea or Concept]
   748   C1960952:mg % [Quantitative Concept]
   748   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   748   C3244317:given [Intellectual Product]
   714 E C0869039:Dose [Quantitative Concept]
   714 E C1114758:Dose # [Clinical Attribute]
   714 E C1428722:DOS [Gene or Genome]
   714 E C1947971:Give [Functional Concept]

Phrase: "per pulse at 1-"

Phrase: "to 4-week intervals"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C1272706:intervals [Temporal Concept]
   793 E C1552654:Interval [Idea or Concept]
   793 E C1552713:Interval [Intellectual Product]

Phrase: "with variable steroid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0038317:Steroid [Steroid]

Phrase: "and"

Phrase: "adjuvant therapy regimens."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C2945654:regimens [Intellectual Product]
   793 E C0040808:Regimen [Therapeutic or Preventive Procedure]
   734   C0677850:adjuvant therapy [Therapeutic or Preventive Procedure]
Processing 00000000.tx.44: Remission was achieved in 112/191 evaluable patients. 

Phrase: "Remission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0544452:Remission [Finding]
  1000   C0687702:remission [Neoplastic Process]

Phrase: "was"

Phrase: "achieved in 112/191 evaluable patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C2986511:evaluable patients [Patient or Disabled Group]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1516986:Evaluable [Disease or Syndrome]
Processing 00000000.tx.45: Relapse occurred in 68/135 patients. 

Phrase: "Relapse"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035020:Relapse [Phenomenon or Process]
  1000   C0205336:relapse [Temporal Concept]
  1000   C0277556:Relapse [Disease or Syndrome]

Phrase: "occurred in 68/135 patients."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0450387:68 [Intellectual Product]
   760   C1709305:Occurred [Activity]
   726 E C2745955:OCCUR [Temporal Concept]
Processing 00000000.tx.46: Leucopenia, infection, haemorrhagic cystitis and death were rare [reviewed in 7]. 

Phrase: "Leucopenia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023530:Leucopenia [Disease or Syndrome]

Phrase: "infection,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009450:Infection, NOS [Disease or Syndrome]
   928 E C0439663:Infected [Functional Concept]
   888 E C0030657:infectivity [Qualitative Concept]

Phrase: "haemorrhagic cystitis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085692:Haemorrhagic cystitis [Disease or Syndrome]
   861   C0010692:Cystitis [Disease or Syndrome]
   861   C1963088:Cystitis [Finding]

Phrase: "and"

Phrase: "death"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011065:Death [Organism Function]
  1000   C1306577:Death, NOS [Finding]

Phrase: "were"

Phrase: "rare"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521114:Rare [Temporal Concept]
  1000   C0522498:Rare [Qualitative Concept]
  1000   C1514917:RARE [Gene or Genome]

Phrase: "["

Phrase: "reviewed in 7"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0282443:reviewed [Intellectual Product]
   790   C1709940:Reviewed [Qualitative Concept]
   756 E C1552617:Review [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.47: The regimen for intravenous CYC in CYCLOPS was designed on the basis of a consensus on the best available evidence and is not identical to the regimens reviewed above. 

Phrase: "The regimen for intravenous CYC"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0040808:Regimen [Therapeutic or Preventive Procedure]
   760   C2945654:regimen [Intellectual Product]

Phrase: "in CYCLOPS"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0266667:Cyclops [Congenital Abnormality]
  1000   C0323854:Cyclops [Eukaryote]

Phrase: "was"

Phrase: "designed on the basis of a consensus"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0376298:Consensus [Social Behavior]
   748   C1527178:Basis [Functional Concept]
   748   C1874451:Basis [Pharmacologic Substance]
   714   C1707689:Design [Activity]
   714   C2983265:DESIGN [Intellectual Product]

Phrase: "on the best available evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332120:Evidence [Functional Concept]

Phrase: "and"

Phrase: "is"

Phrase: "not identical to the regimens"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205280:Identical [Qualitative Concept]

Phrase: "reviewed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0282443:reviewed [Intellectual Product]
  1000   C1709940:Reviewed [Qualitative Concept]
   966 E C1552617:Review [Idea or Concept]

Phrase: "above."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1282910:Above [Spatial Concept]
  1000   C1552828:above [Idea or Concept]
Processing 00000000.tx.48: An analysis of four prospective trials conducted in France concluded that, in 215 patients with polyarteritis nodosa, microscopic polyangiitis or ChurgStrauss syndrome the overall survival was the same in patients receiving CYC and corticosteroids as in those that only received corticosteroids [8]. 

Phrase: "An analysis of four prospective trials"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "conducted in France"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0016674:France [Geographic Area]
   756   C0004927:Conduct [Individual Behavior]

Phrase: "concluded"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that,"

Phrase: "in 215 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with polyarteritis nodosa,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0031036:Polyarteritis Nodosa [Disease or Syndrome]
   861   C0264992:Polyarteritis [Disease or Syndrome]
   805 E C1318520:Necrotizing vasculitis [Disease or Syndrome]

Phrase: "microscopic polyangiitis"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0343192:Microscopic Polyangiitis [Disease or Syndrome]
   861   C0205288:Microscopic [Qualitative Concept]
   861   C0264939:Polyangiitis [Finding]
   789 E C0026018:Microscopies [Laboratory Procedure]

Phrase: "or"

Phrase: "ChurgStrauss syndrome"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039082:Syndrome [Disease or Syndrome]

Phrase: "the overall survival"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0038952:Survival [Activity]
   861   C0220921:survival [Functional Concept]
   861   C0282416:Overall [Intellectual Product]
   861   C1561607:Overall [Qualitative Concept]

Phrase: "was"

Phrase: "the same in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0445247:Same [Qualitative Concept]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "and"

Phrase: "corticosteroids"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0001617:Corticosteroids [Hormone,Pharmacologic Substance,Steroid]
   966 E C3536709:Corticosteroid [Pharmacologic Substance]

Phrase: "as in those"

Phrase: "that only received corticosteroids"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0001617:Corticosteroids [Hormone,Pharmacologic Substance,Steroid]
   793 E C3536709:Corticosteroid [Pharmacologic Substance]

Phrase: "[8"

Phrase: "]."
Processing 00000000.tx.49: Stratification for disease severity suggested that patients with more severe disease (five-factor score 2) had prolonged survival when treated with CYC. 

Phrase: "Stratification for disease severity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1514983:Stratification [Research Activity]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that patients with more severe disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "(five-factor score 2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0205451:Five [Quantitative Concept]
   812   C0449820:Score [Quantitative Concept]
   812   C1521761:Factor [Functional Concept]
   812   C2827422:Factor [Conceptual Entity]

Phrase: ")"

Phrase: "had"

Phrase: "prolonged survival"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0038952:Survival [Activity]
   861   C0220921:survival [Functional Concept]

Phrase: "when"

Phrase: "treated with CYC."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]
   734 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   734 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]
Processing 00000000.tx.50: CYC did not, however, appear to reduce the relapse rate. 

Phrase: "CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "did"

Phrase: "not,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "however,"

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reduce"

Phrase: "the relapse rate."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0035020:Relapse [Phenomenon or Process]
   861   C0205336:relapse [Temporal Concept]
   861   C0277556:Relapse [Disease or Syndrome]
   861   C0871208:Rate [Activity]
   861   C1521828:Rate [Quantitative Concept]
Processing 00000000.tx.51: They concluded that CYC should be used for patients with severe disease at presentation. 

Phrase: "They"

Phrase: "concluded"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "should"

Phrase: "be"

Phrase: "used for patients"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1273517:used [Finding]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]

Phrase: "with severe disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "at presentation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449450:Presentation [Idea or Concept]
Processing 00000000.tx.52: Thus, we now have evidence on which to base the initial therapy for most patients presenting with AAV. 

Phrase: "Thus,"

Phrase: "we now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "have"

Phrase: "evidence on which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332120:Evidence [Functional Concept]

Phrase: "to base"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002055:base [Inorganic Chemical]
  1000   C0178499:Base [Chemical Viewed Functionally]
  1000   C1880279:Base [Biomedical or Dental Material]
   928 E C0205112:Basal [Spatial Concept]
   916 E C0016617:Foundation [Organization]
   916 E C1626935:Bases [Quantitative Concept]

Phrase: "the initial therapy for most patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0039798:therapy [Functional Concept]
   753   C0087111:Therapy [Therapeutic or Preventive Procedure]
   753   C1363945:Therapy [Finding]

Phrase: "presenting with AAV."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   819   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0042384:Vasculitis [Disease or Syndrome]
   770   C0449450:Presenting [Idea or Concept]
   770   C1963274:Vasculitis [Finding]
   737 E C0150312:Present [Quantitative Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.53: Toxicity has already been reduced by the use of lower cumulative doses of CYC. 

Phrase: "Toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]

Phrase: "has"

Phrase: "already"

Phrase: "been"

Phrase: "reduced by the use of lower cumulative doses of CYC."
Meta Candidates (Total=16; Excluded=3; Pruned=0; Remaining=13)
   760   C1524063:Use of [Functional Concept]
   741   C1707814:Dose Reduced [Therapeutic or Preventive Procedure]
   739   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   739   C0042153:use [Functional Concept]
   739   C0178602:Doses [Quantitative Concept]
   739   C0392756:Reduced [Qualitative Concept]
   739   C0441994:Lower [Spatial Concept]
   739   C0457083:Use [Functional Concept]
   739   C1511559:Cumulative [Qualitative Concept]
   739   C1548802:Lower [Body Location or Region]
   739   C1947944:Use [Intellectual Product]
   739   C2003888:Lower [Activity]
   726   C2986497:Cumulative Dose [Conceptual Entity]
   706 E C0869039:Dose [Quantitative Concept]
   706 E C1114758:Dose # [Clinical Attribute]
   706 E C1428722:DOS [Gene or Genome]
Processing 00000000.tx.54: The challenge now is to develop less toxic treatments for use as first-line therapies to replace CYC but also to treat those refractory or intolerant to CYC, and to reduce the toxicity of long-term maintenance therapy. 

Phrase: "The challenge now"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0798503:Challenge [Clinical Attribute]
   861   C0805586:Challenge [Health Care Activity]
   861   C3274764:Challenge [Conceptual Entity]

Phrase: "is"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "develop"

Phrase: "less toxic treatments for use"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   760   C0087111:Treatments [Therapeutic or Preventive Procedure]
   726 E C0039798:treatment [Functional Concept]
   726 E C1522326:Treatment [Functional Concept]
   726 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   726 E C1705169:Treatment [Conceptual Entity]
   726 E C3538994:TREATMENT [Research Activity]

Phrase: "as first-line therapies to"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   890   C1708063:First-Line Therapy [Therapeutic or Preventive Procedure]
   812   C0087111:therapies [Therapeutic or Preventive Procedure]
   812   C0205132:Line [Spatial Concept]
   812   C0205435:First [Quantitative Concept]
   812   C1279901:First [Qualitative Concept]
   812   C1550648:Line [Substance]
   812   C1552960:Line [Quantitative Concept]
   779 E C0039798:therapy [Functional Concept]
   779 E C1363945:Therapy [Finding]

Phrase: "replace"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1554078:Replace [Idea or Concept]

Phrase: "CYC"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "but"

Phrase: "also to"

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "those refractory"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205269:Refractory [Functional Concept]

Phrase: "or"

Phrase: "intolerant to CYC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0231200:Intolerant [Functional Concept]

Phrase: "and"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reduce"

Phrase: "the toxicity of long-term maintenance therapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0040539:toxicity [Qualitative Concept]
   748   C0600688:Toxicity [Injury or Poisoning]
Processing 00000000.tx.55: Over the past 5 yr, there have been rapid developments in the treatment of other forms of autoimmune disease and inevitably these treatments are beginning to be used in vasculitis patients. 

Phrase: "Over the past 5 yr,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439234:yr [Temporal Concept]

Phrase: "there"

Phrase: "have"

Phrase: "been"

Phrase: "rapid developments in the treatment of other forms of autoimmune disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   704   C0243107:development [Physiologic Function]
   704   C0678723:Development [Organism Function]
   704   C1527148:Development [Functional Concept]

Phrase: "and"

Phrase: "inevitably"

Phrase: "these treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "are"

Phrase: "beginning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439659:Beginning [Temporal Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "used in vasculitis patients."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0042384:Vasculitis [Disease or Syndrome]
   770   C1273517:used [Finding]
   770   C1963274:Vasculitis [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.56: Anti-TNF- therapy, initially developed for treatment of RA and inflammatory bowel disease, has proved extremely successful and is now widely used to treat these patients. 

Phrase: "Anti-TNF- therapy,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0281481:anti-TNF therapy [Therapeutic or Preventive Procedure]
   901   C0279936:therapy, TNF [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]

Phrase: "initially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205265:Initially [Temporal Concept]

Phrase: "developed for treatment of RA"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538806:Ra [Spatial Concept]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "and"

Phrase: "inflammatory bowel disease,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0021390:Inflammatory bowel disease [Disease or Syndrome]
   913   C1290884:Inflammatory disease [Disease or Syndrome]
   901   C0021831:bowel disease [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   827   C0021853:Bowel [Body Part, Organ, or Organ Component]
   827   C0333348:Inflammatory [Functional Concept]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "has"

Phrase: "proved"

Phrase: "extremely successful"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1272703:Successful [Qualitative Concept]
   789 E C0597535:Success [Social Behavior]

Phrase: "and"

Phrase: "is"

Phrase: "now widely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1948052:Now [Temporal Concept]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "these patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.57: Other disease, such as ankylosing spondylitis and psoriasis, are being treated using this approach. 

Phrase: "Other disease,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "such as ankylosing spondylitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038013:Ankylosing spondylitis [Disease or Syndrome]
   861   C0038012:Spondylitis [Disease or Syndrome]

Phrase: "and"

Phrase: "psoriasis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033860:Psoriasis [Disease or Syndrome]

Phrase: "are"

Phrase: "being"

Phrase: "treated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "this approach."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449445:Approach [Spatial Concept]
Processing 00000000.tx.58: B-cell depletion therapy with monoclonal antibodies is proving useful in many autoimmune diseases, especially RA and lupus [9, 10]. 

Phrase: "B-cell depletion therapy with monoclonal antibodies"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   853   C1171324:B-Cell Depletion Therapy [Therapeutic or Preventive Procedure]
   804   C0545321:B cell therapy [Therapeutic or Preventive Procedure]
   789   C0279694:antibody monoclonal therapy [Therapeutic or Preventive Procedure]
   774   C0281176:antibodies therapy [Therapeutic or Preventive Procedure]
   774   C0302189:Cell Therapy [Therapeutic or Preventive Procedure]
   748   C0039798:therapy [Functional Concept]
   748   C0087111:Therapy [Therapeutic or Preventive Procedure]
   748   C1363945:Therapy [Finding]

Phrase: "is"

Phrase: "proving"

Phrase: "useful in many autoimmune diseases,"

Phrase: "especially RA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "and"

Phrase: "lupus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024131:Lupus [Disease or Syndrome]
  1000   C0024138:lupus [Disease or Syndrome]
  1000   C0409974:Lupus [Disease or Syndrome]

Phrase: "[9,"

Phrase: "10"

Phrase: "]."
Processing 00000000.tx.59: At present most reports of TNF- blockade in vasculitis relate to case series or small uncontrolled trials. 

Phrase: "At present most"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]

Phrase: "reports of TNF- blockade"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0332206:Blockade [Functional Concept]
   770   C0684224:Report [Intellectual Product]
   770   C0700287:Report [Health Care Activity]
   770   C3273238:Report [Intellectual Product]
   770   C3540676:Blockade [Pharmacologic Substance]

Phrase: "in vasculitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042384:Vasculitis [Disease or Syndrome]
  1000   C1963274:Vasculitis [Finding]

Phrase: "relate to case series"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0150093:Case Series [Research Activity]
   770   C0163712:Relate [Organic Chemical]
   770   C0205549:Series [Quantitative Concept]
   770   C0868928:Case [Functional Concept]
   770   C1706255:CASE [Medical Device]
   770   C1706256:Case [Conceptual Entity]
   770   C2348044:Series [Intellectual Product]

Phrase: "or"

Phrase: "small uncontrolled trials."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0008976:Trial [Research Activity]
Processing 00000000.tx.60: In the USA, the WGET placebo-controlled trial of etanercept in Wegener's granulomatosis reported that in 180 patients etanercept was not effective at either induction or maintenance of disease remission when used in addition to conventional therapy [11]. 

Phrase: "In the USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "the WGET placebo-controlled trial of etanercept"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0008976:Trial [Research Activity]

Phrase: "in Wegener's granulomatosis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0043092:Wegener Granulomatosis [Disease or Syndrome]
   861   C0521173:Granulomatosis [Disease or Syndrome]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that in 180 patients etanercept"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0717758:Etanercept [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "not effective at either induction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280519:effective [Qualitative Concept]
   760   C1704419:Effective [Qualitative Concept]

Phrase: "or"

Phrase: "maintenance of disease remission"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0024501:Maintenance [Activity]

Phrase: "when"

Phrase: "used in addition to conventional therapy"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   790   C2945704:Conventional Therapy [Therapeutic or Preventive Procedure]
   753   C0039798:therapy [Functional Concept]
   753   C0087111:Therapy [Therapeutic or Preventive Procedure]
   753   C0439858:Conventional [Qualitative Concept]
   753   C1273517:used [Finding]
   753   C1363945:Therapy [Finding]
   753   C1883712:Addition [Functional Concept]
   748   C1706712:Additional Therapy [Finding]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]

Phrase: "[11"

Phrase: "]."
Processing 00000000.tx.61: In the UK, infliximab has been used in active disease both at first presentation and relapse, as well in persistent disease. 

Phrase: "In the UK,"

Phrase: "infliximab"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0666743:infliximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "has"

Phrase: "been"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "in active disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "both at first presentation"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0439629:First presentation [Temporal Concept]
   770   C0205435:First [Quantitative Concept]
   770   C0238767:Both [Spatial Concept]
   770   C0449450:Presentation [Idea or Concept]
   770   C1279901:First [Qualitative Concept]
   770   C1706086:Both [Qualitative Concept]

Phrase: "and"

Phrase: "relapse,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035020:Relapse [Phenomenon or Process]
  1000   C0205336:relapse [Temporal Concept]
  1000   C0277556:Relapse [Disease or Syndrome]

Phrase: "as well"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205170:Well [Qualitative Concept]
  1000   C3146287:Well [Manufactured Object]

Phrase: "in persistent disease."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C2983415:Persistent Disease [Finding]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.62: Remission was induced in 88% of 32 patients, but there was a significant infection rate (21%) and 20% patients relapsed [12]. 

Phrase: "Remission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0544452:Remission [Finding]
  1000   C0687702:remission [Neoplastic Process]

Phrase: "was"

Phrase: "induced in 88% of 32 patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0205263:Induced [Functional Concept]

Phrase: "but"

Phrase: "there"

Phrase: "was"

Phrase: "a significant infection rate"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0009450:Infection, NOS [Disease or Syndrome]
   827   C0871208:Rate [Activity]
   827   C1521828:Rate [Quantitative Concept]
   755 E C0439663:Infected [Functional Concept]
   716 E C0030657:infectivity [Qualitative Concept]

Phrase: "(21%"

Phrase: ")"

Phrase: "and"

Phrase: "20% patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "relapsed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205336:relapsed [Temporal Concept]
   966 E C0035020:Relapse [Phenomenon or Process]
   966 E C0277556:Relapse [Disease or Syndrome]

Phrase: "[12"

Phrase: "]."
Processing 00000000.tx.63: Similarly, there are several promising small-scale studies looking at B cell depletion using rituximab. 

Phrase: "Similarly,"

Phrase: "there"

Phrase: "are"

Phrase: "several promising small-scale studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   804   C0947630:studies [Laboratory Procedure]
   771 E C0557651:Study [Manufactured Object]
   771 E C2603343:Study [Research Activity]

Phrase: "looking at B cell depletion"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   806   C0004561:B-cell [Cell]
   760   C0007634:Cell [Cell]
   760   C0333668:Depletion [Functional Concept]
   760   C1269647:Cell [Cell]
   760   C1704653:Cell [Medical Device]
   760   C1948049:Cell [Spatial Concept]
   726   C0233426:look [Organism Attribute]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "rituximab."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0393022:rituximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.64: Antithymocyte globulin may be effective in an open trial of patients with refractory Wegener's granulomatosis; 

Phrase: "Antithymocyte globulin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003442:Anti-Thymocyte Globulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0017649:Globulin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "may"

Phrase: "be"

Phrase: "effective in an open trial of patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280519:effective [Qualitative Concept]
   748   C1704419:Effective [Qualitative Concept]

Phrase: "with refractory Wegener's granulomatosis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0043092:Wegener Granulomatosis [Disease or Syndrome]
   827   C0521173:Granulomatosis [Disease or Syndrome]

Phrase: ";"
Processing 00000000.tx.65: 13 of 15 patients responded with either a partial or complete response, but seven patients relapsed during a mean follow-up of 8.4 months [13]. 

Phrase: "13 of 15 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "responded with either"

Phrase: "a partial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0728938:Partial [Quantitative Concept]
  1000   C1550516:partial [Idea or Concept]

Phrase: "or"

Phrase: "complete response,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0677874:Complete Response [Finding]
   861   C0205197:Complete [Qualitative Concept]
   861   C0725685:COMPLEAT [Food]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]
   789 E C0439812:Completeness [Qualitative Concept]

Phrase: "but"

Phrase: "seven patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "relapsed during a mean"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C0205336:relapsed [Temporal Concept]
   770   C0444504:Mean [Quantitative Concept]
   770   C2347634:Mean [Quantitative Concept]
   770   C2348143:Mean [Quantitative Concept]
   737 E C0035020:Relapse [Phenomenon or Process]
   737 E C0277556:Relapse [Disease or Syndrome]

Phrase: "follow-up of 8.4 months"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0589120:Follow-up [Finding]
   790   C1522577:follow-up [Health Care Activity]
   790   C1704685:FOLLOW-UP [Intellectual Product]
   790   C3274571:FOLLOW-UP [Health Care Activity]
   753   C0332283:follow [Temporal Concept]
   753   C1719822:Follow [Intellectual Product]

Phrase: "[13"

Phrase: "]."
Processing 00000000.tx.66: Translational research is the process by which developments in basic science are developed to provide novel therapies in the clinic. 

Phrase: "Translational research"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C3494163:Translational Research [Research Activity]
   861   C0035168:research [Research Activity]
   861   C0242481:Research [Research Activity]

Phrase: "is"

Phrase: "the process by which developments"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1184743:Process [Body Part, Organ, or Organ Component]
   760   C1522240:Process [Phenomenon or Process]
   756   C1511806:Developmental Process [Organ or Tissue Function]

Phrase: "in basic science"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681833:Basic Science [Research Activity]
   861   C0036397:Science [Occupation or Discipline]

Phrase: "are"

Phrase: "developed"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "novel therapies in the clinic."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   760   C0087111:therapies [Therapeutic or Preventive Procedure]
   726 E C0039798:therapy [Functional Concept]
   726 E C1363945:Therapy [Finding]
Processing 00000000.tx.67: The aetiology of AAV remains unknown. 

Phrase: "The aetiology of AAV remains"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C1292714:Associated aetiology [Functional Concept]
   753   C0015127:aetiology [Functional Concept]
   753   C1314792:Aetiology [Functional Concept]
   753   C1524003:Etiology [Conceptual Entity]

Phrase: "unknown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439673:Unknown [Qualitative Concept]
Processing 00000000.tx.68: However, understanding of disease pathogenesis has improved. 

Phrase: "However,"

Phrase: "understanding of disease pathogenesis"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0012634:Disease [Disease or Syndrome]
   770   C0162340:Understanding [Mental Process]
   770   C0543483:pathogenesis [Functional Concept]
   770   C0699748:Pathogenesis [Pathologic Function]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "has"

Phrase: "improved."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0184511:Improved [Qualitative Concept]
  1000   C0332272:Improved [Qualitative Concept]
  1000   C1561611:Improved [Intellectual Product]
Processing 00000000.tx.69: It has become increasingly clear that ANCA are important in disease pathogenesis. 

Phrase: "It"

Phrase: "has"

Phrase: "become"

Phrase: "increasingly"

Phrase: "clear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]

Phrase: "that ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "are"

Phrase: "important in disease pathogenesis."
Processing 00000000.tx.70: These autoantibodies recognize proteinase 3 (PR3) or myeloperoxidase (MPO) presented on the surface of cytokine-primed neutrophils or monocytes, allowing cell activation with release of reactive oxygen species, cytokines and degranulation. 

Phrase: "These autoantibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "recognize"

Phrase: "proteinase 3 (PR3)"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1335267:PROTEINASE 3 [Gene or Genome]
   861   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C1622131:proteinase [Molecular Function]
   861   C1947941:Proteinase [Enzyme]

Phrase: "or"

Phrase: "myeloperoxidase (MPO)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "presented on the surface of cytokine-primed neutrophils"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   744   C0027950:Neutrophils [Cell]
   744   C0079189:cytokine [Amino Acid, Peptide, or Protein,Immunologic Factor]
   744   C0205148:Surface [Spatial Concept]
   744   C0449450:Presented [Idea or Concept]
   744   C0871133:primed [Functional Concept]
   711 E C0150312:Present [Quantitative Concept]

Phrase: "or"

Phrase: "monocytes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0026473:Monocytes [Cell]

Phrase: "allowing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowing [Social Behavior]

Phrase: "cell activation with release of reactive oxygen species,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1326120:cell activation [Cell Function]
   744   C1879547:Activation [Activity]

Phrase: "cytokines"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079189:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1524094:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "degranulation."
Processing 00000000.tx.71: Activation of neutrophils requires antigen engagement via the Fab portion of the antibody with surface-expressed PR3 or MPO and ligation of Fc receptors, both FcRIIa and FcRIIIb, for full activation. 

Phrase: "Activation of neutrophils"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   841   C0242599:Neutrophil Activation [Physiologic Function]
   790   C1879547:Activation [Activity]

Phrase: "requires"

Phrase: "antigen engagement via the Fab portion of the antibody"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0425152:engagement [Finding]
   742   C2937292:engagement [Finding]

Phrase: "with surface-expressed PR3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   861   C1335267:PROTEINASE 3 [Gene or Genome]
   812   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   812   C1622131:proteinase [Molecular Function]
   812   C1947941:Proteinase [Enzyme]

Phrase: "or"

Phrase: "MPO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "ligation of Fc receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0023690:Ligation [Therapeutic or Preventive Procedure]

Phrase: "both FcRIIa"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1448238:FcRIIA [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "and"

Phrase: "FcRIIIb,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0966831:FcRIIIB [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]

Phrase: "for full activation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1879547:Activation [Activity]
Processing 00000000.tx.72: ANCA signalling differs from that described for most immune complex signalling via Fc receptors. 

Phrase: "ANCA signalling"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C3537152:signalling [Biologic Function]
   827 E C1710082:Signal [Phenomenon or Process]

Phrase: "differs from that"

Phrase: "described for most immune complex signalling"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C0003313:Immune complex [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0439662:Immune [Functional Concept]
   753   C0439855:Complex [Qualitative Concept]
   753   C1552738:described [Idea or Concept]
   753   C1704241:Complex [Chemical Viewed Structurally]
   753   C3537152:signalling [Biologic Function]
   719 E C1710082:Signal [Phenomenon or Process]

Phrase: "via Fc receptors."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034805:Receptors, Fc [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]
   861   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   861   C2983605:FC [Activity]
Processing 00000000.tx.73: ANCA F(ab')2 fragments stimulate G-protein-coupled pathways; 

Phrase: "ANCA F(ab')2 fragments"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   804   C0332255:fragments [Functional Concept]
   804   C0486805:Fragments [Body Substance]
   771 E C1708096:Fragment [Qualitative Concept]

Phrase: "stimulate"

Phrase: "G-protein-coupled pathways"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1704259:Pathways [Molecular Function]
   812   C1705987:Pathways [Conceptual Entity]

Phrase: ";"
Processing 00000000.tx.74: this alone is necessary but not sufficient to generate a respiratory burst. 

Phrase: "this alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "is"

Phrase: "necessary"

Phrase: "but"

Phrase: "not sufficient to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205410:Sufficient [Qualitative Concept]
   827   C1518422:Not [Functional Concept]

Phrase: "generate"

Phrase: "a respiratory burst."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0085416:Respiratory Burst [Cell Function]
   861   C0439818:burst [Qualitative Concept]
   861   C0521346:respiratory [Functional Concept]
   861   C1546767:Respiratory [Intellectual Product]
   861   C1881705:BURST [Phenomenon or Process]
Processing 00000000.tx.75: Fc receptor signalling activates Syk kinase, protein kinase C and calcium release, and both F(ab')2 and Fc engagement are required for protein kinase B activity, culminating in the generation of a respiratory burst. 

Phrase: "Fc receptor signalling"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C3537152:signalling [Biologic Function]
   793 E C1710082:Signal [Phenomenon or Process]
   734   C0034805:Fc Receptor [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]

Phrase: "activates"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "Syk kinase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1698931:Syk kinase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "protein kinase C"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0033634:Protein Kinase C [Amino Acid, Peptide, or Protein,Enzyme]
   913   C0033621:Protein C [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   913   C1168438:Protein C [Laboratory Procedure]
   913   C1418943:PROTEIN C [Gene or Genome]
   913   C3540567:Protein C [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "calcium release,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "both F(ab')2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Fc engagement"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0425152:engagement [Finding]
   861   C2937292:engagement [Finding]

Phrase: "are"

Phrase: "required for protein kinase B activity,"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   833   C0164786:Protein Kinase B [Amino Acid, Peptide, or Protein,Enzyme]
   833   C0285558:Protein Kinase B [Amino Acid, Peptide, or Protein,Enzyme]
   820   C1150527:protein kinase activity [Molecular Function]
   802 E C2261495:protein phosphokinase activity [Molecular Function]
   790   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   783   C0377800:protein B [Amino Acid, Peptide, or Protein,Receptor]
   783   C1150423:kinase activity [Molecular Function]
   783   C1537044:protein activity [Molecular Function]
   753   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1514873:Required [Functional Concept]
   753   C1561536:*Activity [Idea or Concept]

Phrase: "culminating in the generation of a respiratory burst."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0085416:Respiratory Burst [Cell Function]
   744   C0079411:Generation [Temporal Concept]
   744   C0205260:Culminating [Qualitative Concept]
   744   C0439818:burst [Qualitative Concept]
   744   C0521346:respiratory [Functional Concept]
   744   C1546767:Respiratory [Intellectual Product]
   744   C1881705:BURST [Phenomenon or Process]
   744   C3146294:Generation [Activity]
Processing 00000000.tx.76: For full activation, engagement of 2 integrins is also important, as neutrophils are unable to generate a respiratory burst without 2 integrin ligation [for review see 14]. 

Phrase: "For full activation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1879547:Activation [Activity]

Phrase: "engagement of 2 integrins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0425152:engagement [Finding]
   770   C2937292:engagement [Finding]

Phrase: "is"

Phrase: "also important,"

Phrase: "as"

Phrase: "neutrophils"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0027950:Neutrophils [Cell]
   916 E C0746885:neutrophilic [Cell Function]
   893 E C0151683:Neutrophilia [Finding]

Phrase: "are"

Phrase: "unable to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1299582:Unable [Finding]

Phrase: "generate"

Phrase: "a respiratory burst without 2 integrin ligation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0085416:Respiratory Burst [Cell Function]
   748   C0439818:burst [Qualitative Concept]
   748   C0521346:respiratory [Functional Concept]
   748   C1546767:Respiratory [Intellectual Product]
   748   C1881705:BURST [Phenomenon or Process]

Phrase: "["

Phrase: "for review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "14"

Phrase: "]."
Processing 00000000.tx.77: ANCA are predominantly of the immunoglobulin G (IgG) isotype. 

Phrase: "ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "are"

Phrase: "predominantly of the immunoglobulin G (IgG) isotype."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0020852:Immunoglobulin G [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   790   C3536873:Immunoglobulin G [Pharmacologic Substance]
   783   C0021017:Immunoglobulin isotype [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Isotype
   753   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0439267:g% [Quantitative Concept]
   753   C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.78: The IgG subclass of ANCA may also be important in neutrophil activation. 

Phrase: "The IgG subclass of ANCA"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1275917:Immunoglobulin G subclass [Amino Acid, Peptide, or Protein,Immunologic Factor]
   783   C1302677:Immunoglobulin subclass [Classification]
   753   C0445604:Subclass [Classification]

Phrase: "may"

Phrase: "also"

Phrase: "be"

Phrase: "important in neutrophil activation."
Processing 00000000.tx.79: Renal relapses of Wegener's granulomatosis are correlated with increases in the level of IgG3, although other studies suggest that pathogenicity is correlated with IgG1 and/or IgG4. 

Phrase: "Renal relapses of Wegener's granulomatosis"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   760   C0035020:Relapses [Phenomenon or Process]
   726 E C0205336:relapse [Temporal Concept]
   726 E C0277556:Relapse [Disease or Syndrome]

Phrase: "are"

Phrase: "correlated with increases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0442805:increases [Functional Concept]
   790   C1707520:Correlated [Qualitative Concept]

Phrase: "in the level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0441889:Level [Qualitative Concept]
  1000   C0456079:Level [Classification]
  1000   C1547707:Level [Geographic Area]
  1000   C2946261:Level [Pharmacologic Substance]

Phrase: "of IgG3,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020859:IgG3 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2828356:IgG3 [Cell Component]

Phrase: "although"

Phrase: "other studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that pathogenicity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0030657:pathogenicity [Qualitative Concept]
  1000   C1136169:Pathogenicity [Organism Attribute]
   928 E C0450254:Pathogenic [Organism]

Phrase: "is"

Phrase: "correlated with IgG1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0020855:IgG1 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   790   C1707520:Correlated [Qualitative Concept]

Phrase: "and/or"

Phrase: "IgG4."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020860:IgG4 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2828357:IgG4 [Cell Component]
Processing 00000000.tx.80: IgG4 is reported to bind only FcRI receptors, which are not constitutively expressed on neutrophils. 

Phrase: "IgG4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020860:IgG4 [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2828357:IgG4 [Cell Component]

Phrase: "is"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "bind"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1145667:Bind [Activity]
  1000   C1167622:bind [Molecular Function]

Phrase: "only FcRI receptors,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "which"

Phrase: "are"

Phrase: "not constitutively"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "expressed on neutrophils."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0027950:Neutrophils [Cell]
   706 E C0746885:neutrophilic [Cell Function]
Processing 00000000.tx.81: However, recent studies have suggested that isolated IgG4 with ANCA activity can activate neutrophils via FcRIIIB [15]. 

Phrase: "However,"

Phrase: "recent studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that isolated IgG4 with ANCA activity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0020860:IgG4 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C2828357:IgG4 [Cell Component]

Phrase: "can"

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "neutrophils via FcRIIIB"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0027950:Neutrophils [Cell]
   706 E C0746885:neutrophilic [Cell Function]

Phrase: "[15"

Phrase: "]."
Processing 00000000.tx.82: Other properties in addition to IgG subclass may also influence the biological outcome of activation of neutrophils by ANCA. 

Phrase: "Other properties in addition to IgG subclass"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   744   C0871161:properties [Qualitative Concept]
   744   C1292721:properties [Functional Concept]
   711 E C1882134:Property [Conceptual Entity]
   711 E C2347695:Property [Entity]

Phrase: "may"

Phrase: "also"

Phrase: "influence"

Phrase: "the biological outcome of activation of neutrophils"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1274040:Outcome [Functional Concept]

Phrase: "by ANCA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]
Processing 00000000.tx.83: Polyclonal IgG isolated from ANCA-positive patients has a high proportion of hypogalactosylated IgG. 

Phrase: "Polyclonal IgG"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0020852:Immunoglobulin G [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   901   C3536873:Immunoglobulin G [Pharmacologic Substance]
   827   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0439267:g% [Quantitative Concept]
   827   C1621846:immunoglobulin [Molecular Function]

Phrase: "isolated from ANCA-positive patients"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   806   C0238874:ANCA POSITIVE [Laboratory or Test Result]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0103647:ANCA [Immunologic Factor]
   760   C0205409:Isolated [Functional Concept]
   760   C0439178:% Positive [Quantitative Concept]
   760   C1446409:Positive [Qualitative Concept]
   760   C1514241:Positive [Finding]
   760   C1548221:Isolated [Idea or Concept]
   760   C2825490:Positive [Qualitative Concept]
   726 E C0370215:Isolate [Substance]
   726 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "has"

Phrase: "a high proportion of hypogalactosylated IgG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1709707:Proportion [Quantitative Concept]
Processing 00000000.tx.84: In other autoimmune diseases, such as RA, increased hypogalactosylated IgG is also present, and can activate the complement system by via mannose-binding lectin activation. 

Phrase: "In other autoimmune diseases,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0004364:Autoimmune Diseases [Disease or Syndrome]
   861   C0012634:Diseases [Disease or Syndrome]
   861   C0443146:Autoimmune [Pathologic Function]
   789 E C1836721:MALS [Finding]
   789 E C3538764:MALS [Gene or Genome]
   789 E C3540595:MAL [Gene or Genome]

Phrase: "such as RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538806:Ra [Spatial Concept]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "hypogalactosylated IgG"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0020852:Immunoglobulin G [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   901   C3536873:Immunoglobulin G [Pharmacologic Substance]
   827   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0439267:g% [Quantitative Concept]
   827   C1621846:immunoglobulin [Molecular Function]

Phrase: "is"

Phrase: "also"

Phrase: "present"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0150312:Present [Quantitative Concept]
  1000   C0449450:Present [Idea or Concept]

Phrase: ","

Phrase: "and"

Phrase: "can"

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "the complement system by"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0009498:Complement [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0449913:System [Functional Concept]
   770   C1553451:System [Manufactured Object]
   770   C1704459:System [Medical Device]

Phrase: "via mannose-binding lectin activation."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C1879547:Activation [Activity]
   756   C0065661:Mannose Binding Lectin [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   756   C1148594:mannose binding lectin [Molecular Function]
   756   C1417054:MANNOSE-BINDING LECTIN [Gene or Genome]
   756   C2347054:Mannose-Binding Lectin [Amino Acid, Peptide, or Protein]
Processing 00000000.tx.85: ANCA recognize conformational epitopes on MPO and PR3 [for review see 16]. 

Phrase: "ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "recognize"

Phrase: "conformational epitopes on MPO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0003316:Epitopes [Immunologic Factor]

Phrase: "and"

Phrase: "PR3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1335267:PROTEINASE 3 [Gene or Genome]
   861   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C1622131:proteinase [Molecular Function]
   861   C1947941:Proteinase [Enzyme]

Phrase: "["

Phrase: "for review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "16"

Phrase: "]."
Processing 00000000.tx.86: Despite the apparent requirement for a tertiary structure, there are reports of PR3-ANCA binding to linear peptides and MPO-ANCA binding to the heavy chain of MPO, using recombinant deletion mutants. 

Phrase: "Despite the apparent requirement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1514873:Requirement [Functional Concept]

Phrase: "for a tertiary structure,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205372:Tertiary [Quantitative Concept]
   861   C0678594:Structure [Spatial Concept]

Phrase: "there"

Phrase: "are"

Phrase: "reports of PR3-ANCA binding"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0684224:Reports [Intellectual Product]
   753   C0700287:reports [Health Care Activity]
   719 E C3273238:Report [Intellectual Product]

Phrase: "to linear peptides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030956:Peptides [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "MPO-ANCA binding to the heavy chain of MPO,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0243122:binding [Functional Concept]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "recombinant deletion mutants."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596988:mutants [Cell or Molecular Dysfunction]
Processing 00000000.tx.87: The epitopes recognized by ANCA are restricted, as competition studies of PR3-ANCA or MPO-ANCA with monoclonal antibodies to PR3 or MPO inhibit binding by patient ANCA. 

Phrase: "The epitopes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003316:Epitopes [Immunologic Factor]

Phrase: "recognized by ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0103647:ANCA [Immunologic Factor]

Phrase: "are"

Phrase: "restricted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443288:Restricted [Functional Concept]

Phrase: ","

Phrase: "as"

Phrase: "competition studies of PR3-ANCA"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   753   C0679932:competition [Social Behavior]
   753   C0947630:studies [Laboratory Procedure]
   719 E C0557651:Study [Manufactured Object]
   719 E C2603343:Study [Research Activity]

Phrase: "or"

Phrase: "MPO-ANCA with monoclonal antibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0103647:ANCA [Immunologic Factor]

Phrase: "to PR3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1335267:PROTEINASE 3 [Gene or Genome]
   861   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C1622131:proteinase [Molecular Function]
   861   C1947941:Proteinase [Enzyme]

Phrase: "or"

Phrase: "MPO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "binding by patient ANCA."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
Processing 00000000.tx.88: The most antigenic site of PR3 appears to be around or in the catalytic site. 

Phrase: "The most antigenic site of PR3"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C2945843:Site of [Qualitative Concept]
   748   C0205145:Site [Spatial Concept]
   748   C1515974:Site [Body Location or Region]
   748   C2825164:Site [Spatial Concept]

Phrase: "appears"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be around"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C2987476:Be [Conceptual Entity]

Phrase: "or in the catalytic site."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0205681:Catalytic Site [Functional Concept]
   806   C0600499:catalytic site [Amino Acid Sequence]
   760   C0007382:Catalytic [Natural Phenomenon or Process]
   760   C0205145:Site [Spatial Concept]
   760   C1515974:Site [Body Location or Region]
   760   C2825164:Site [Spatial Concept]
Processing 00000000.tx.89: Biosensor technology studies suggest an immunodominant epitope common to all PR3-ANCA from patients at initial presentation, as these antibodies recognize overlapping regions on PR3. 

Phrase: "Biosensor technology studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "an immunodominant epitope"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003316:Epitope [Immunologic Factor]

Phrase: "common to all PR3-ANCA"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0205214:Common [Quantitative Concept]
   753   C1522138:Common [Functional Concept]
   753   C3245511:common [Intellectual Product]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "at initial presentation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449976:Initial presentation [Functional Concept]
   861   C0449450:Presentation [Idea or Concept]

Phrase: "as"

Phrase: "these antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   966 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "recognize"

Phrase: "overlapping regions on PR3."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0017446:Region [Geographic Area]
   726   C0205147:Region [Spatial Concept]
Processing 00000000.tx.90: The epitopes recognized by these antibodies may change over time or depending on disease activity. 

Phrase: "The epitopes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003316:Epitopes [Immunologic Factor]

Phrase: "recognized by these antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   737 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "may"

Phrase: "change over time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0040223:Time [Temporal Concept]
   827   C3541383:Time [Temporal Concept]
   771 E C0442043:Temporal [Spatial Concept]
   771 E C2362314:Temporal [Temporal Concept]
   743 E C1632851:Times [Quantitative Concept]

Phrase: "or"

Phrase: "depending on disease activity."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   770   C0012634:Disease [Disease or Syndrome]
   770   C0205177:Activity [Functional Concept]
   770   C0439167:% activity [Quantitative Concept]
   770   C0441655:Activity [Activity]
   770   C1561536:*Activity [Idea or Concept]
   737   C0725813:depend [Medical Device]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.91: However unlike in SLE, where epitope spreading may involve different autoantigens, epitope spreading in ANCA-associated vasculitis is only observed within MPO or PR3. 

Phrase: "However unlike"

Phrase: "in SLE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024141:SLE NOS [Disease or Syndrome]

Phrase: "where epitope"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003316:Epitope [Immunologic Factor]

Phrase: "spreading"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0332261:Spreading [Qualitative Concept]
   966 E C1947932:Spread [Activity]

Phrase: "may"

Phrase: "involve"

Phrase: "different autoantigens,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0004359:Autoantigens [Immunologic Factor]

Phrase: "epitope"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003316:Epitope [Immunologic Factor]

Phrase: "spreading in ANCA-associated vasculitis"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   862   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   760   C0042384:Vasculitis [Disease or Syndrome]
   760   C0103647:ANCA [Immunologic Factor]
   760   C0332261:Spreading [Qualitative Concept]
   760   C0332281:Associated [Qualitative Concept]
   760   C1963274:Vasculitis [Finding]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
   726 E C1947932:Spread [Activity]

Phrase: "is"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "observed within MPO"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]
   790   C1441672:Observed [Functional Concept]

Phrase: "or"

Phrase: "PR3."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1335267:PROTEINASE 3 [Gene or Genome]
   861   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C1622131:proteinase [Molecular Function]
   861   C1947941:Proteinase [Enzyme]
Processing 00000000.tx.92: Immunohistochemistry studies of renal biopsies from patients have shown neutrophils adherent to the endothelium and trapped within the glomerulus. 

Phrase: "Immunohistochemistry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021044:Immunohistochemistry [Laboratory Procedure]

Phrase: "studies of renal biopsies"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   819   C0846101:renal study [Diagnostic Procedure]
   816   C0194073:Renal biopsy [Diagnostic Procedure]
   770   C0005558:biopsies [Diagnostic Procedure]
   770   C0022646:Renal [Body Part, Organ, or Organ Component]
   770   C0557651:Study [Manufactured Object]
   770   C0947630:studies [Laboratory Procedure]
   770   C2603343:Study [Research Activity]
   737 E C0220797:biopsy [Functional Concept]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "neutrophils"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0027950:Neutrophils [Cell]
   916 E C0746885:neutrophilic [Cell Function]
   893 E C0151683:Neutrophilia [Finding]

Phrase: "adherent to the endothelium"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0334154:Adherent [Functional Concept]

Phrase: "and"

Phrase: "trapped within the glomerulus."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0022663:Glomerulus [Body Part, Organ, or Organ Component]
   770   C0184047:Trapped [Medical Device]
Processing 00000000.tx.93: In vitro, activation of neutrophils by ANCA induces actin polymerization, with increased cell rigidity [17] and cell adhesion to TNF-primed endothelial cells potentially resulting in trapping of neutrophils within the microvasculature. 

Phrase: "In vitro, activation of neutrophils"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   781   C0242599:Neutrophil Activation [Physiologic Function]
   760   C1879547:Activation [Activity]

Phrase: "by ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "actin polymerization,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1155982:actin polymerization [Cell Function]
   861   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "with increased cell rigidity"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0026837:Rigidity, NOS [Sign or Symptom]
   827   C0700109:rigidity [Natural Phenomenon or Process]
   755 E C0231517:Rigid [Individual Behavior]
   755 E C1882952:RIGID [Phenomenon or Process]

Phrase: "[17"

Phrase: "]"

Phrase: "and"

Phrase: "cell adhesion to TNF-primed endothelial cells potentially"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   808   C2754808:endothelial cell-cell adhesion [Cell Function]
   778   C1154382:cell-cell adhesion [Cell Function]
   770   C0007577:Cell Adhesion [Cell Function]
   744   C0001511:Adhesion [Pathologic Function]
   744   C0175633:Adhesion [Natural Phenomenon or Process]

Phrase: "resulting in trapping of neutrophils"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   806   C0332294:Resulting in [Functional Concept]
   760   C0027950:Neutrophils [Cell]
   760   C0678226:resulting [Functional Concept]
   726 E C1274040:Result [Functional Concept]
   726 E C1546471:Result [Idea or Concept]
   726 E C2825142:Result [Finding]

Phrase: "within the microvasculature."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0243079:microvasculature [Organ or Tissue Function]
  1000   C2350571:Microvasculature [Body Part, Organ, or Organ Component]
Processing 00000000.tx.94: Unlike the generation of a respiratory burst, actin polymerization does not depend on TNF priming and correlates with the expression of PR3 on the cell surface [18]. 

Phrase: "Unlike the generation"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0079411:Generation [Temporal Concept]
  1000   C3146294:Generation [Activity]
   907 E C1414672:Genesis [Gene or Genome]
   907 E C2984892:Genesis [Gene or Genome]

Phrase: "of a respiratory burst,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0085416:Respiratory Burst [Cell Function]
   861   C0439818:burst [Qualitative Concept]
   861   C0521346:respiratory [Functional Concept]
   861   C1546767:Respiratory [Intellectual Product]
   861   C1881705:BURST [Phenomenon or Process]

Phrase: "actin polymerization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1155982:actin polymerization [Cell Function]
   861   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "depend on TNF priming"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0725813:depend [Medical Device]
   770   C0871133:Priming [Functional Concept]

Phrase: "and"

Phrase: "correlates with the expression of PR3"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
   778   C1335267:PROTEINASE 3 [Gene or Genome]
   748   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]
   748   C1622131:proteinase [Molecular Function]
   748   C1947941:Proteinase [Enzyme]

Phrase: "on the cell surface"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0699040:Cell surface [Cell Component]
   861   C0205148:Surface [Spatial Concept]

Phrase: "[18"

Phrase: "]."
Processing 00000000.tx.95: In static assays, ANCA activation of neutrophils results in adhesion and endothelial cell lysis. 

Phrase: "In static assays,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0005507:Assay [Laboratory Procedure]
   827   C0243073:assay [Qualitative Concept]
   827   C1510438:Assay [Laboratory Procedure]

Phrase: "ANCA activation of neutrophils"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   802   C0242599:Neutrophil Activation [Physiologic Function]
   770   C1879547:Activation [Activity]

Phrase: "results in adhesion"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0001511:Adhesion [Pathologic Function]
   790   C0175633:Adhesion [Natural Phenomenon or Process]
   790   C1274040:Result [Functional Concept]
   790   C1546471:Result [Idea or Concept]
   790   C2825142:Result [Finding]

Phrase: "and"

Phrase: "endothelial cell lysis."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0024348:Lysis [Pathologic Function]
   827   C1536403:lysis [Cell Function]
   755 E C0439680:Lytic [Qualitative Concept]
   734   C0225336:Endothelial cell [Cell]
Processing 00000000.tx.96: However, under flow conditions, which mimic the shear stresses present in vessels, ANCA promotes the adherence of neutrophils to primed endothelial cells and promotes transmigration. 

Phrase: "However,"

Phrase: "under flow conditions,"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "which"

Phrase: "mimic"

Phrase: "the shear stresses"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   966   C1171318:shear stress [Natural Phenomenon or Process]
   861   C0175735:shear [Medical Device]
   861   C0205013:shear [Therapeutic or Preventive Procedure]
   827   C0038435:Stress [Finding]
   777 E C0231297:Stressful [Functional Concept]

Phrase: "present in vessels,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0005847:Vessels [Body Part, Organ, or Organ Component]
   790   C0150312:Present [Quantitative Concept]
   790   C0449450:Present [Idea or Concept]
   756 E C1511228:Vessel [Tissue]
   718 E C0702235:Vasal [Organic Chemical,Pharmacologic Substance]

Phrase: "ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "the adherence of neutrophils"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1510802:Adherence [Functional Concept]

Phrase: "to primed endothelial cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   901   C0225336:Endothelial Cells [Cell]
   827   C0007634:Cells [Cell]
   827   C0014257:Endothelial [Tissue]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "transmigration."
Processing 00000000.tx.97: This requires 2 integrin and the chemokine receptor CXCR2, suggesting synergy between signals from CXCR2 and those provided by ANCA to promote neutrophil activation [19]. 

Phrase: "This"

Phrase: "requires"

Phrase: "2 integrin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021701:Integrin [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]

Phrase: "and"

Phrase: "the chemokine receptor CXCR2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1334126:CXCR2 [Gene or Genome]
   827   C1704986:CXCR2 [Gene or Genome]
   734   C0524914:chemokine receptor [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "synergy between signals"

Phrase: "from CXCR2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1334126:CXCR2 [Gene or Genome]
  1000   C1704986:CXCR2 [Gene or Genome]

Phrase: "and"

Phrase: "those"

Phrase: "provided by ANCA to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0103647:ANCA [Immunologic Factor]
   770   C1999230:Provided [Activity]

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "neutrophil activation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0242599:Neutrophil Activation [Physiologic Function]
   861   C1879547:Activation [Activity]

Phrase: "[19"

Phrase: "]."
Processing 00000000.tx.98: Ongoing studies are addressing endothelial damage in this model. 

Phrase: "Ongoing studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0549178:ONGOING [Idea or Concept]
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "are"

Phrase: "addressing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0376649:Address [Intellectual Product]
   966   C1442065:Address [Spatial Concept]

Phrase: "endothelial damage in this model."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0010957:Damage [Injury or Poisoning]
   760   C1883709:Damage [Functional Concept]
Processing 00000000.tx.99: ANCA may also be important in frustrating the normal anti-inflammatory pathways that promote the resolution of inflammation. 

Phrase: "ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "may"

Phrase: "also"

Phrase: "be"

Phrase: "important in frustrating"

Phrase: "the normal anti-inflammatory pathways"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1704259:Pathways [Molecular Function]
   812   C1705987:Pathways [Conceptual Entity]

Phrase: "that"

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "the resolution of inflammation."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1514893:Resolution [Idea or Concept]
   770   C1706463:Resolution [Quantitative Concept]
   770   C2699488:Resolution [Conceptual Entity]
Processing 00000000.tx.100: As neutrophils constitutively undergo apoptosis (programmed cell death), there is increased expression of PR3 and MPO on the cell surface, allowing binding by ANCA. 

Phrase: "As neutrophils constitutively"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0027950:Neutrophils [Cell]
   777 E C0746885:neutrophilic [Cell Function]
   755 E C0151683:Neutrophilia [Finding]

Phrase: "undergo"

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "(programmed cell death"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0162638:Programmed Cell Death [Cell Function]
   901   C0007587:Cell Death [Cell Function]
   827   C0007634:Cell [Cell]
   827   C0011065:Death [Organism Function]
   827   C1269647:Cell [Cell]
   827   C1306577:Death, NOS [Finding]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]

Phrase: ")"

Phrase: ","

Phrase: "there"

Phrase: "is"

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "expression of PR3"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "MPO on the cell surface,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "allowing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowing [Social Behavior]

Phrase: "binding by ANCA."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
Processing 00000000.tx.101: This does not result in activation, but these opsonized apoptotic cells show increased phagocytosis by macrophages in a proinflammatory manner, with release of IL-8 [20]. 

Phrase: "This"

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "result in activation,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1274040:Result [Functional Concept]
   790   C1546471:Result [Idea or Concept]
   790   C1879547:Activation [Activity]
   790   C2825142:Result [Finding]

Phrase: "but"

Phrase: "these opsonized apoptotic cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "increased phagocytosis by macrophages"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1372517:Increased Phagocytosis [Cell Function]
   770   C0031308:Phagocytosis [Cell Function]

Phrase: "in a proinflammatory manner,"

Phrase: "with release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030685:Release [Health Care Activity]
  1000   C0391871:Release [Functional Concept]
  1000   C0439180:% release [Quantitative Concept]
  1000   C0680255:release [Health Care Activity]
  1000   C1283071:Release [Functional Concept]
  1000   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "of IL-8"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0079633:IL 8 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0020898:IL [Geographic Area]
   861   C0021764:IL [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0022271:IL [Geographic Area]

Phrase: "[20"

Phrase: "]."
Processing 00000000.tx.102: Macrophages generally phagocytose apoptotic cells in a non-phlogistic manner with release of the immune-suppressing cytokine TGF-. 

Phrase: "Macrophages generally"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0024432:Macrophages [Cell]
   861   C1546706:Macrophages [Intellectual Product]
   861   C1550652:Macrophages [Body Substance]

Phrase: "phagocytose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0031308:phagocytose [Cell Function]

Phrase: "apoptotic cells in a non-phlogistic manner"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   748   C0007634:Cells [Cell]
   748   C3282337:Cells [Cell]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "with release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030685:Release [Health Care Activity]
  1000   C0391871:Release [Functional Concept]
  1000   C0439180:% release [Quantitative Concept]
  1000   C0680255:release [Health Care Activity]
  1000   C1283071:Release [Functional Concept]
  1000   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "of the immune-suppressing cytokine TGF-."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0040691:TGF [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C1527194:TGF [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.103: ANCA may also frustrate the process of neutrophils becoming apoptotic. 

Phrase: "ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "may"

Phrase: "also"

Phrase: "frustrate"

Phrase: "the process of neutrophils"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1184743:Process [Body Part, Organ, or Organ Component]
   770   C1522240:Process [Phenomenon or Process]

Phrase: "becoming"

Phrase: "apoptotic."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1516044:Apoptotic [Qualitative Concept]
   928 E C0162638:Apoptosis [Cell Function]
Processing 00000000.tx.104: Pathologically, ANCA-associated vasculitis is characterized by leucocytoclasis, and electron microscopy studies have suggested that there may be a defect in the clearance of apoptotic neutrophils. 

Phrase: "Pathologically,"

Phrase: "ANCA-associated vasculitis"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   827   C0042384:Vasculitis [Disease or Syndrome]
   827   C0103647:ANCA [Immunologic Factor]
   827   C0332281:Associated [Qualitative Concept]
   827   C1963274:Vasculitis [Finding]
   793 E C0750490:Associate [Idea or Concept]
   793 E C1706221:Associate [Professional or Occupational Group]

Phrase: "is"

Phrase: "characterized by leucocytoclasis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1880022:Characterized [Activity]

Phrase: "and"

Phrase: "electron microscopy studies"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   965   C0026019:Electron microscopic study [Laboratory Procedure]
           Electron Microscopy
   901   C2984656:ELECTRON MICROSCOPY [Functional Concept]
   827   C0013852:Electron [Quantitative Concept]
   827   C0026018:Microscopy [Laboratory Procedure]
   827   C0947630:studies [Laboratory Procedure]
   827   C3463986:Electron [Bird]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]
   755 E C0013850:Electronic [Manufactured Object]
   755 E C0205288:Microscopic [Qualitative Concept]
   755 E C1547561:Electronic [Idea or Concept]

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that there"

Phrase: "may"

Phrase: "be"

Phrase: "a defect in the clearance of apoptotic neutrophils."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1457869:Defect [Functional Concept]
   744   C1861101:DEFECT [Disease or Syndrome]
Processing 00000000.tx.105: There is evidence of leucocytes with degraded nuclear material undergoing disintegration in tissues [21], and apoptotic cells have been observed in ANCA-positive renal vasculitis [22]. 

Phrase: "There"

Phrase: "is"

Phrase: "evidence of leucocytes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   882   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "with degraded nuclear material"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0520510:Material [Substance]

Phrase: "undergoing"

Phrase: "disintegration in tissues"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1265875:Disintegration [Acquired Abnormality]

Phrase: "[21"

Phrase: "],"

Phrase: "and"

Phrase: "apoptotic cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "have"

Phrase: "been"

Phrase: "observed in ANCA-positive renal vasculitis"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0152002:Renal vasculitis [Disease or Syndrome]
   790   C0238874:ANCA POSITIVE [Laboratory or Test Result]
   753   C0022646:Renal [Body Part, Organ, or Organ Component]
   753   C0042384:Vasculitis [Disease or Syndrome]
   753   C0103647:ANCA [Immunologic Factor]
   753   C0439178:% Positive [Quantitative Concept]
   753   C1441672:Observed [Functional Concept]
   753   C1446409:Positive [Qualitative Concept]
   753   C1514241:Positive [Finding]
   753   C1963274:Vasculitis [Finding]
   753   C2825490:Positive [Qualitative Concept]

Phrase: "[22"

Phrase: "]."
Processing 00000000.tx.106: In vitro, neutrophils activated by ANCA show accelerated nuclear changes of apoptosis in a manner dependent on reactive oxygen species. 

Phrase: "In vitro, neutrophils"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   827   C0027950:Neutrophils [Cell]
   743 E C0746885:neutrophilic [Cell Function]
   734   C0021135:In Vitro [Intellectual Product]
   734   C1533691:in vitro [Qualitative Concept]
   734   C2827718:In Vitro [Functional Concept]
   721 E C0151683:Neutrophilia [Finding]

Phrase: "activated by ANCA"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0103647:ANCA [Immunologic Factor]
   790   C1879547:Activated [Activity]
   756 E C1515877:Activate [Functional Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "accelerated nuclear changes of apoptosis"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   820   C1159823:apoptotic nuclear changes [Cell Function]
   760   C0392747:changes [Functional Concept]
   760   C0443172:changes [Quantitative Concept]
   726 E C1705241:Change [Quantitative Concept]

Phrase: "in a manner"

Phrase: "dependent on reactive oxygen species."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0851827:Dependent [Qualitative Concept]
   760   C1701901:Dependent [Qualitative Concept]
   760   C3244310:dependent [Functional Concept]
Processing 00000000.tx.107: However, the surface changes of apoptosis that allow macrophages to recognize apoptotic cells (i.e. surface expression of phosphatidylserine) are uncoupled from the nuclear changes. 

Phrase: "However,"

Phrase: "the surface"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205148:Surface [Spatial Concept]

Phrase: "changes of apoptosis"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0162638:Apoptosis [Cell Function]
   790   C0392747:Change [Functional Concept]
   790   C0443172:change [Quantitative Concept]
   790   C1705241:Change [Quantitative Concept]
   718 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "that"

Phrase: "allow"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allow [Social Behavior]

Phrase: "macrophages to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0024432:Macrophages [Cell]
   861   C1546706:Macrophages [Intellectual Product]
   861   C1550652:Macrophages [Body Substance]

Phrase: "recognize"

Phrase: "apoptotic cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(i.e. surface expression of phosphatidylserine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0185117:Expression [Therapeutic or Preventive Procedure]
   753   C0205148:Surface [Spatial Concept]

Phrase: ")"

Phrase: "are"

Phrase: "uncoupled from the nuclear changes."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0392747:changes [Functional Concept]
   760   C0443172:changes [Quantitative Concept]
   760   C0521447:Nuclear [Spatial Concept]
   726 E C1705241:Change [Quantitative Concept]
Processing 00000000.tx.108: This allows neutrophils to undergo secondary necrosis as they are not phagocytosed by macrophages [23]. 

Phrase: "This"

Phrase: "allows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allow [Social Behavior]

Phrase: "neutrophils to"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0027950:Neutrophils [Cell]
   777 E C0746885:neutrophilic [Cell Function]
   755 E C0151683:Neutrophilia [Finding]

Phrase: "undergo"

Phrase: "secondary necrosis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0027540:Necrosis [Organ or Tissue Function]
   861   C1334928:Necrosis [Finding]

Phrase: "as"

Phrase: "they"

Phrase: "are"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "phagocytosed by macrophages"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0024432:Macrophages [Cell]
   790   C1546706:Macrophages [Intellectual Product]
   790   C1550652:Macrophages [Body Substance]
   756   C0031308:phagocytose [Cell Function]

Phrase: "[23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "]."
Processing 00000000.tx.109: This is interesting, as pyocyanin, a toxin released by Pseudomonas infection, accelerates neutrophil apoptosis in a manner which is also dependent on reactive oxygen species, frustrating the resolution of infection and inflammation in patients with cystic fibrosis [24]. 

Phrase: "This"

Phrase: "is"

Phrase: "interesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0543488:interesting [Mental Process]

Phrase: ","

Phrase: "as"

Phrase: "pyocyanin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034211:Pyocyanin [Biologically Active Substance,Organic Chemical]

Phrase: "a toxin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040549:Toxin [Biologically Active Substance,Hazardous or Poisonous Substance]

Phrase: "released by Pseudomonas infection,"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   833   C0033817:Pseudomonas infection [Disease or Syndrome]
   770   C0009450:Infection, NOS [Disease or Syndrome]
   770   C0033808:Pseudomonas [Bacterium]
   770   C0391871:Released [Functional Concept]
   770   C1283071:Released [Functional Concept]
   737 E C0030685:Release [Health Care Activity]
   737 E C0439180:% release [Quantitative Concept]
   737 E C0680255:release [Health Care Activity]
   737 E C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "accelerates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521110:accelerate [Functional Concept]

Phrase: "neutrophil apoptosis in a manner"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1326212:neutrophil apoptosis [Cell Function]
   760   C0162638:Apoptosis [Cell Function]

Phrase: "which"

Phrase: "is"

Phrase: "also dependent on reactive oxygen species,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0851827:Dependent [Qualitative Concept]
   753   C1701901:Dependent [Qualitative Concept]
   753   C3244310:dependent [Functional Concept]

Phrase: "frustrating"

Phrase: "the resolution of infection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1514893:Resolution [Idea or Concept]
   770   C1706463:Resolution [Quantitative Concept]
   770   C2699488:Resolution [Conceptual Entity]

Phrase: "and"

Phrase: "inflammation in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0021368:Inflammation [Pathologic Function]

Phrase: "with cystic fibrosis"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0010674:Cystic Fibrosis [Disease or Syndrome]
   861   C0016059:Fibrosis [Pathologic Function]
   861   C0205207:Cystic [Qualitative Concept]
   789 E C0010709:Cyst [Disease or Syndrome]
   789 E C0334129:Fibrotic [Functional Concept]
   789 E C0686883:Cyst [Eukaryote]

Phrase: "[24"

Phrase: "]."
Processing 00000000.tx.110: Despite the considerable evidence that ANCA have important biological effects in vitro, demonstrating this in vivo has proved more difficult. 

Phrase: "Despite the considerable evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332120:Evidence [Functional Concept]

Phrase: "that ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "have"

Phrase: "important biological effects"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0005532:Biological [Biomedical Occupation or Discipline]
   827   C0205460:biological [Qualitative Concept]
   827   C1280500:effects [Qualitative Concept]
   793 E C2348382:Effect [Qualitative Concept]

Phrase: "in vitro,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]

Phrase: "demonstrating"

Phrase: "this in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "has"

Phrase: "proved"

Phrase: "more difficult."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0332218:Difficult [Qualitative Concept]
   789 E C1299586:Difficulty [Finding]
Processing 00000000.tx.111: In early studies from Brouwer et al., immunization of rats with MPO did not by itself lead to vasculitis. 

Phrase: "In early studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "from Brouwer et al.,"

Phrase: "immunization of rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0020971:Immunisation [Therapeutic or Preventive Procedure]
   790   C0042196:immunisation [Therapeutic or Preventive Procedure]
   790   C3244291:immunization [Functional Concept]

Phrase: "with MPO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "did"

Phrase: "not by itself"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1518422:Not [Functional Concept]

Phrase: "lead to vasculitis."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   790   C0042384:Vasculitis [Disease or Syndrome]
   790   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   790   C1522538:Lead [Functional Concept]
   790   C1963274:Vasculitis [Finding]
   790   C2348269:Lead [Element, Ion, or Isotope]
   790   C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.112: However, when the products of activated neutrophils, including MPO and its substrate, H2O2, were perfused into the renal artery in these animals, they developed a severe pauci-immune crescentic nephritis [25]. 

Phrase: "However,"

Phrase: "when"

Phrase: "the products of activated neutrophils,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1514468:Products [Entity]
   726 E C1704444:Product [Quantitative Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "MPO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "its substrate,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1710236:Substrate [Manufactured Object]

Phrase: "H2O2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020281:H2O2 [Inorganic Chemical,Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "were"

Phrase: "perfused into the renal artery"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0035065:Renal Artery [Body Part, Organ, or Organ Component]
   806   C1278951:Renal artery [Body Part, Organ, or Organ Component]
   760   C0003842:Artery [Body Part, Organ, or Organ Component]
   760   C0022646:Renal [Body Part, Organ, or Organ Component]
   760   C0226004:artery [Body System]
   726   C1549542:Perfuse [Functional Concept]

Phrase: "in these animals,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "they"

Phrase: "developed"

Phrase: "a severe pauci-immune crescentic nephritis"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   804   C0027697:Nephritis [Disease or Syndrome]
   711 E C0022646:Kidney [Body Part, Organ, or Organ Component]
   711 E C0227665:kidney [Body Part, Organ, or Organ Component]
   711 E C1278978:Kidney [Body Part, Organ, or Organ Component]
   711 E C1514845:KIDNEY [Tissue]

Phrase: "[25"

Phrase: "]."
Processing 00000000.tx.113: Subsequently, Yang et al. reported the presence of immune complexes in the glomeruli of a similar model, and suggested that the mechanism involved may therefore be different from that in the human disease [26]. 

Phrase: "Subsequently,"

Phrase: "Yang et al."

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "the presence of immune complexes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "in the glomeruli"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   966   C0022663:Glomerulus [Body Part, Organ, or Organ Component]
   916 E C0268731:GLOMERULAR [Disease or Syndrome]

Phrase: "of a similar model,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3161035:Model [Intellectual Product]

Phrase: "and"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441712:Mechanism [Functional Concept]
  1000   C1706376:Mechanism [Manufactured Object]

Phrase: "involved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involved [Functional Concept]

Phrase: "may"

Phrase: "therefore"

Phrase: "be"

Phrase: "different from that"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1705242:Different [Qualitative Concept]
   718 E C1705241:*Difference [Quantitative Concept]

Phrase: "in the human disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "[26"

Phrase: "]."
Processing 00000000.tx.114: In a further study, the in vivo effects of ANCA were demonstrated in rats immunized with MPO and then given a small subnephritic dose of anti-glomerular basement membrane (GBM) antibodies. 

Phrase: "In a further study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "the in vivo effects of ANCA"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "were"

Phrase: "demonstrated in rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0034693:rats [Mammal]
   790   C0034721:Rats [Mammal]

Phrase: "immunized with MPO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "a small subnephritic dose of anti-glomerular basement membrane (GBM) antibodies."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C0178602:Dose [Quantitative Concept]
   739   C0869039:Dose [Quantitative Concept]
   739   C1114758:Dose # [Clinical Attribute]
Processing 00000000.tx.115: These animals developed a severe crescentic nephritis, whereas controls immunized with MPO alone or given anti-GBM antibodies alone did not [27]. 

Phrase: "These animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "developed"

Phrase: "a severe crescentic nephritis,"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   827   C0027697:Nephritis [Disease or Syndrome]
   734 E C0022646:Kidney [Body Part, Organ, or Organ Component]
   734 E C0227665:kidney [Body Part, Organ, or Organ Component]
   734 E C1278978:Kidney [Body Part, Organ, or Organ Component]
   734 E C1514845:KIDNEY [Tissue]

Phrase: "whereas"

Phrase: "controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "immunized with MPO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "or"

Phrase: "given anti-GBM antibodies"
Meta Candidates (Total=16; Excluded=3; Pruned=0; Remaining=13)
   936   C0052055:Anti-glomerular basement membrane antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Glomerular basement membrane antibody
   876   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0599297:Glomerular Basement Membrane [Body Part, Organ, or Organ Component]
   859 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   844   C0368737:Basement membrane Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0004799:Basement membrane [Tissue]
   799   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   799   C0022663:Glomerular [Body Part, Organ, or Organ Component]
   799   C0025255:Membrane [Tissue]
   799   C0268731:GLOMERULAR [Disease or Syndrome]
   799   C0596901:Membrane [Cell Component]
   799   C1706182:Membrane [Manufactured Object]
   799   C1979853:Basement [Cell Component]
   766 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   727 E C0205287:Membranous [Qualitative Concept]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "did"

Phrase: "not [27"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "]."
Processing 00000000.tx.116: More recently, two new animal models have provided stronger evidence that ANCA are directly pathogenic. 

Phrase: "More recently,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205172:More [Functional Concept]
   861   C0332185:Recently [Temporal Concept]

Phrase: "two new animal models"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0599779:Models, Animal [Animal]
   812   C0003062:Animal [Animal]
   812   C3161035:Models [Intellectual Product]

Phrase: "have"

Phrase: "provided"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provided [Activity]

Phrase: "stronger"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   966   C0442821:Strong [Qualitative Concept]
   916 E C0237897:Strength [Quantitative Concept]
   916 E C0808080:Strength [Idea or Concept]
   916 E C1705922:Strength [Qualitative Concept]

Phrase: "evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332120:Evidence [Functional Concept]

Phrase: "that ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "are"

Phrase: "directly pathogenic."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0450254:Pathogenic [Organism]
   789 E C0030657:pathogenicity [Qualitative Concept]
   789 E C1136169:Pathogenicity [Organism Attribute]
Processing 00000000.tx.117: Xiao and colleagues immunized MPO-knockout mice with mouse MPO to achieve a strong autoimmune response. 

Phrase: "Xiao"

Phrase: "and"

Phrase: "colleagues"

Phrase: "immunized"

Phrase: "MPO-knockout mice with mouse MPO to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0206745:Knock-out Mice [Mammal]
   774   C0025914:mouse, mice [Mammal]
           Mice
   748   C0025929:mice [Mammal]
   748   C0026809:Mice [Mammal]

Phrase: "achieve"

Phrase: "a strong autoimmune response."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0004366:Autoimmune Response [Pathologic Function]
   827   C0443146:Autoimmune [Pathologic Function]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
Processing 00000000.tx.118: Splenocytes from these mice, when transferred to Rag2 knockout mice, led to the development of crescentic nephritis and systemic vasculitis in the recipients. 

Phrase: "Splenocytes from these mice,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1519477:Splenocyte [Cell]

Phrase: "when"

Phrase: "transferred to Rag2 knockout mice,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   806   C0206745:Knock-out Mice [Mammal]
   760   C0025914:Mice [Mammal]
   760   C0025929:mice [Mammal]
   760   C0026809:Mice [Mammal]
   760   C0348011:transferred [Functional Concept]
   760   C0560617:knock out [Injury or Poisoning]
   760   C1419248:RAG2 [Gene or Genome]
   760   C1522225:Knock-out [Experimental Model of Disease]
   760   C1567709:RAG-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C2698932:RAG-2 [Gene or Genome]
   726 E C0040671:Transfer [Mental Process]
   726 E C1705822:Transfer [Activity]

Phrase: "led to the development of crescentic nephritis"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
   748   C0027697:Nephritis [Disease or Syndrome]
   748   C0243107:development [Physiologic Function]
   748   C0678723:Development [Organism Function]
   748   C1527148:Development [Functional Concept]
   748   C1708698:LED [Manufactured Object]
   728   C1171312:development kidney [Organ or Tissue Function]
   714 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   714 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   714 E C1522538:Lead [Functional Concept]
   714 E C2348269:Lead [Element, Ion, or Isotope]
   714 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "systemic vasculitis in the recipients."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0264939:Systemic Vasculitis [Finding]
   760   C0042384:Vasculitis [Disease or Syndrome]
   760   C0205373:Systemic [Functional Concept]
   760   C1963274:Vasculitis [Finding]
Processing 00000000.tx.119: Anti-MPO antibodies, purified from the serum of the immunized MPO knockout mice, were injected intravenously into both Rag2-knockout and wild-type recipients. 

Phrase: "Anti-MPO antibodies,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   913   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   896 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0443920:Myeloperoxidase antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]
   793 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "purified from the serum of the immunized MPO knockout mice,"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   760   C0206745:Knock-out Mice [Mammal]
   739   C0025914:Mice [Mammal]
   739   C0025929:mice [Mammal]
   739   C0026809:Mice [Mammal]
   739   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0229671:Serum [Body Substance]
   739   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]
   739   C0560617:knock out [Injury or Poisoning]
   739   C1522225:Knock-out [Experimental Model of Disease]
   739   C1546774:Serum [Intellectual Product]
   739   C1550100:Serum [Body Substance]
   739   C1998793:Purified [Functional Concept]

Phrase: "were"

Phrase: "injected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1720154:Inject [Functional Concept]

Phrase: "intravenously into both Rag2-knockout"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0560617:knock out [Injury or Poisoning]
   760   C1419248:RAG2 [Gene or Genome]
   760   C1522225:Knock-out [Experimental Model of Disease]
   760   C1567709:RAG-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C2698932:RAG-2 [Gene or Genome]

Phrase: "and"

Phrase: "wild-type recipients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C1709854:Recipient [Human]
   734   C1883559:Wild Type [Organism Attribute]
Processing 00000000.tx.120: The recipient mice developed pauci-immune focal necrotizing crescentic nephritis, demonstrating that anti-MPO antibodies alone were sufficient to cause disease [28]. 

Phrase: "The recipient mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "developed"

Phrase: "pauci-immune focal necrotizing crescentic nephritis,"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   799   C0027697:Nephritis [Disease or Syndrome]
   706 E C0022646:Kidney [Body Part, Organ, or Organ Component]
   706 E C0227665:kidney [Body Part, Organ, or Organ Component]
   706 E C1278978:Kidney [Body Part, Organ, or Organ Component]
   706 E C1514845:KIDNEY [Tissue]

Phrase: "demonstrating"

Phrase: "that anti-MPO antibodies"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   913   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   896 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0443920:Myeloperoxidase antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]
   793 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "were"

Phrase: "sufficient to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205410:Sufficient [Qualitative Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "[28"

Phrase: "]."
Processing 00000000.tx.121: The second new model, described by Pusey's group, has so far only been reported in abstracts [29, 30]. 

Phrase: "The second new model,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C3161035:Model [Intellectual Product]

Phrase: "described by Pusey's group,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0441833:Group [Idea or Concept]
   770   C0687744:group [Population Group]
   770   C1257890:Group [Population Group]
   770   C1552516:Group [Health Care Related Organization]
   770   C1552738:described [Idea or Concept]
   770   C1705428:Group [Conceptual Entity]
   770   C1705429:Group [Population Group]

Phrase: "has"

Phrase: "so far only"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0037640:SO [Geographic Area]
   827   C0205108:far [Spatial Concept]
   827   C0205171:Only [Quantitative Concept]
   827   C1720467:Only [Intellectual Product]

Phrase: "been"

Phrase: "reported in abstracts"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   790   C0600678:Abstracts [Intellectual Product]
   790   C0684224:Reported [Intellectual Product]
   790   C0700287:Reported [Health Care Activity]
   790   C3496591:Reported [Clinical Attribute]
   756 E C0000857:Abstract [Occupational Activity]
   756 E C1552863:Abstract [Idea or Concept]
   756 E C3273238:Report [Intellectual Product]

Phrase: "[29,"

Phrase: "30"

Phrase: "]."
Processing 00000000.tx.122: WKY rats immunized with human MPO developed a high titre of MPO antibodies, together with pauci-immune crescentic nephritis and lung haemorrhage. 

Phrase: "WKY rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034709:Rats, WKY [Mammal]
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]

Phrase: "immunized with human MPO"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0086418:Human [Human]
   770   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "developed"

Phrase: "a high titre of MPO antibodies,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   803   C0476442:High antibody titer [Finding]
   783   C0474643:antibodies titre [Laboratory Procedure]
   783   C1287242:antibodies titre [Laboratory or Test Result]
   753   C0475208:Titer [Quantitative Concept]

Phrase: "together with pauci-immune crescentic nephritis"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   812   C0027697:Nephritis [Disease or Syndrome]
   719 E C0022646:Kidney [Body Part, Organ, or Organ Component]
   719 E C0227665:kidney [Body Part, Organ, or Organ Component]
   719 E C1278978:Kidney [Body Part, Organ, or Organ Component]
   719 E C1514845:KIDNEY [Tissue]

Phrase: "and"

Phrase: "lung haemorrhage."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0151701:LUNG HEMORRHAGE [Pathologic Function]
  1000   C1963171:Lung hemorrhage [Finding]
   972 E C0475713:Pulmonary hemorrhage [Pathologic Function]
   861   C0019080:Haemorrhage [Pathologic Function]
Processing 00000000.tx.123: This model has been termed experimental autoimmune vasculitis (EAV). 

Phrase: "This model"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3161035:Model [Intellectual Product]

Phrase: "has"

Phrase: "been"

Phrase: "termed experimental autoimmune vasculitis (EAV)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1328843:Autoimmune vasculitis [Disease or Syndrome]
   812   C0042384:Vasculitis [Disease or Syndrome]
   812   C1963274:Vasculitis [Finding]
Processing 00000000.tx.124: The use of intravital microscopy allowed in vivo observation of mesenteric vessels in these rats. 

Phrase: "The use of intravital microscopy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1524063:Use of [Functional Concept]
   760   C0042153:use [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]

Phrase: "allowed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowed [Social Behavior]

Phrase: "in vivo observation of mesenteric vessels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0302523:Observation [Research Activity]
   753   C0700325:observation [Health Care Activity]
   753   C1964257:Observation [Diagnostic Procedure]

Phrase: "in these rats."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]
Processing 00000000.tx.125: Animals with EAV showed enhanced adhesion and transmigration of leucocytes in response to GRO- (CXCL-1), compared with BSA-immunized controls. 

Phrase: "Animals with EAV"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   781   C0003064:experimental animal [Animal]
   760   C0003062:Animals [Animal]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "enhanced adhesion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0001511:Adhesion [Pathologic Function]
   861   C0175633:Adhesion [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "transmigration of leucocytes"

Phrase: "in response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to GRO- (CXCL-1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1332652:GRO [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C1705593:GRO [Gene or Genome]

Phrase: ")"

Phrase: ","

Phrase: "compared with BSA-immunized controls."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C1707455:Compared [Activity]
   726   C0243148:control [Qualitative Concept]
   726   C1550141:Control [Substance]
   726   C1882979:Control [Conceptual Entity]
   726   C2587213:Control [Functional Concept]
   726   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.126: Furthermore, transfer of anti-MPO antibodies from rats with EAV to naive recipients led to increased leucocyte adhesion, even without an inflammatory stimulus, and increased transmigration and microvascular haemorrhage following GRO-. 

Phrase: "Furthermore,"

Phrase: "transfer of anti-MPO antibodies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0040671:Transfer [Mental Process]
   760   C1705822:Transfer [Activity]

Phrase: "from rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: "with EAV"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1328843:Autoimmune vasculitis [Disease or Syndrome]
   827   C0042384:Vasculitis [Disease or Syndrome]
   827   C1963274:Vasculitis [Finding]

Phrase: "to naive recipients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1709854:Recipient [Human]

Phrase: "led to increased leucocyte adhesion,"
Meta Candidates (Total=13; Excluded=5; Pruned=0; Remaining=8)
   806   C1154393:leukocyte adhesion [Cell Function]
   781   C0861064:increased lead [Finding]
   760   C0001511:Adhesion [Pathologic Function]
   760   C0023516:Leucocyte [Cell]
   760   C0175633:Adhesion [Natural Phenomenon or Process]
   760   C0205217:Increased [Quantitative Concept]
   760   C0442805:Increased [Functional Concept]
   760   C1708698:LED [Manufactured Object]
   726 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   726 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   726 E C1522538:Lead [Functional Concept]
   726 E C2348269:Lead [Element, Ion, or Isotope]
   726 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "even without an inflammatory stimulus,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0234402:Stimulus [Phenomenon or Process]
   760   C0333348:Inflammatory [Functional Concept]

Phrase: "and"

Phrase: "increased transmigration"

Phrase: "and"

Phrase: "microvascular haemorrhage"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0019080:Haemorrhage [Pathologic Function]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "GRO-."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1332652:GRO [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1705593:GRO [Gene or Genome]
Processing 00000000.tx.127: This work provides further compelling evidence for the pathogenicity of ANCA. 

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "provides"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0359589:provides [Food]
  1000   C1999230:Provide [Activity]

Phrase: "further compelling evidence for the pathogenicity of ANCA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0332120:Evidence of [Functional Concept]
           Evidence
Processing 00000000.tx.128: The developments described above highlight potential novel therapeutic targets. 

Phrase: "The developments"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0243107:development [Physiologic Function]
   966   C0678723:Development [Organism Function]
   966   C1527148:Development [Functional Concept]
   916 E C0458003:Developmental [Qualitative Concept]

Phrase: "described above highlight potential novel therapeutic targets."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   748   C0039796:Therapeutic [Therapeutic or Preventive Procedure]
   748   C0205314:Novel [Temporal Concept]
   748   C0302350:Therapeutic [Functional Concept]
   748   C0679622:novel [Intellectual Product]
   748   C1552738:described [Idea or Concept]
   748   C3245505:Potential [Qualitative Concept]
   714   C1521840:Target [Functional Concept]
   714   C2986546:TARGET [Diagnostic Procedure]
Processing 00000000.tx.129: For example, the role of 2 integrin and the chemokine receptor CXCR2 in promoting ANCA-associated neutrophil activation and that of ANCA in frustrating the resolution of inflammation and neutrophil apoptosis suggest that modulation of these processes might be useful therapeutic avenues to explore in the future. 

Phrase: "For example,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707959:Example [Conceptual Entity]

Phrase: "the role of 2 integrin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "the chemokine receptor CXCR2 in promoting ANCA-associated neutrophil activation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C1334126:CXCR2 [Gene or Genome]
   739   C1704986:CXCR2 [Gene or Genome]

Phrase: "and"

Phrase: "that of ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0103647:ANCA [Immunologic Factor]

Phrase: "in frustrating"

Phrase: "the resolution of inflammation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1514893:Resolution [Idea or Concept]
   770   C1706463:Resolution [Quantitative Concept]
   770   C2699488:Resolution [Conceptual Entity]

Phrase: "and"

Phrase: "neutrophil apoptosis"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1326212:neutrophil apoptosis [Cell Function]
   861   C0162638:Apoptosis [Cell Function]
   789 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that modulation of these processes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0443264:Modulation [Spatial Concept]

Phrase: "might"

Phrase: "be"

Phrase: "useful therapeutic avenues to"

Phrase: "explore in the future."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016884:Future [Temporal Concept]
Processing 00000000.tx.130: It seemed appropriate with these recent developments in our understanding of the immunopathogenesis of AAV to hold a second meeting with the objective of discussing recent scientific developments and how these could be moved forward into the clinic. 

Phrase: "It"

Phrase: "seemed"

Phrase: "appropriate with these recent developments"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1548787:Appropriate [Qualitative Concept]

Phrase: "in our understanding"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0162340:Understanding [Mental Process]

Phrase: "of the immunopathogenesis"

Phrase: "of AAV to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0042384:Vasculitis [Disease or Syndrome]
   827   C1963274:Vasculitis [Finding]

Phrase: "hold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1553387:Hold [Idea or Concept]
  1000   C1948035:Hold [Activity]

Phrase: "a second meeting with the objective of discussing recent scientific developments"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0556656:Meeting [Health Care Activity]

Phrase: "and"

Phrase: "how"

Phrase: "these"

Phrase: "could"

Phrase: "be"

Phrase: "moved"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C1269909:moved [Functional Concept]
  1000   C1299988:moved [Functional Concept]
  1000   C2699029:Moved [Activity]
   966 E C0560560:move [Organism Function]
   966 E C0578671:move [Finding]

Phrase: "forward into the clinic."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0002424:Clinic [Health Care Related Organization,Manufactured Object]
   770   C0439780:Forward [Spatial Concept]
   770   C0442592:Clinic [Health Care Related Organization,Manufactured Object]
Processing 00000000.tx.131: This meeting was held recently in Cambridge, and over the next few months we will be publishing a series of review articles arising from this symposium, which hopefully will provoke discussion and stimulate the development of new protocols to treat this fascinating group of patients. 

Phrase: "This meeting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0556656:Meeting [Health Care Activity]

Phrase: "was"

Phrase: "held"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1948036:held [Idea or Concept]
  1000   C2987518:hELD [Amino Acid, Peptide, or Protein]
   966 E C1553387:Hold [Idea or Concept]
   966 E C1948035:Hold [Activity]

Phrase: "recently in Cambridge,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332185:Recently [Temporal Concept]

Phrase: "and over the next few months"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   753   C0205117:next [Spatial Concept]
   753   C0332282:Next [Temporal Concept]
   753   C0439231:months [Temporal Concept]
   753   C1515981:And [Idea or Concept]
   753   C1883708:Next [Temporal Concept]
   719 E C0439507:/month [Temporal Concept]

Phrase: "we"

Phrase: "will"

Phrase: "be"

Phrase: "publishing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034037:Publishing [Occupational Activity]

Phrase: "a series of review articles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205549:Series [Quantitative Concept]
   760   C2348044:Series [Intellectual Product]

Phrase: "arising from this symposium,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0086047:symposium [Human-caused Phenomenon or Process]
   770   C0332284:arising [Qualitative Concept]

Phrase: "which hopefully"

Phrase: "will"

Phrase: "provoke"

Phrase: "discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557061:Discussion [Therapeutic or Preventive Procedure]
  1000   C2584313:Discussion [Social Behavior]

Phrase: "and"

Phrase: "stimulate"

Phrase: "the development of new protocols to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C0872253:protocol development [Research Activity]
   753   C0243107:development [Physiologic Function]
   753   C0678723:Development [Organism Function]
   753   C1527148:Development [Functional Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "this fascinating group of patients."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0441833:Group [Idea or Concept]
   760   C0687744:group [Population Group]
   760   C1257890:Group [Population Group]
   760   C1552516:Group [Health Care Related Organization]
   760   C1705428:Group [Conceptual Entity]
   760   C1705429:Group [Population Group]
Processing 00000000.tx.132: J. 

Phrase: "J."
Processing 00000000.tx.133: Levy received support from Schering Plough for the pilot study of infliximab in vasculitis. 

Phrase: "Levy received support from Schering Plough"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0183683:Support [Medical Device]
   753   C1521721:Support [Conceptual Entity]

Phrase: "for the pilot study"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0031928:Pilot Study [Research Activity]
   861   C0473169:Pilot [Professional or Occupational Group]
   861   C0557651:Study [Manufactured Object]
   861   C1414316:PILOT [Gene or Genome]
   861   C2603343:Study [Research Activity]

Phrase: "of infliximab"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0666743:infliximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "in vasculitis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042384:Vasculitis [Disease or Syndrome]
  1000   C1963274:Vasculitis [Finding]
Processing 00000000.tx.134: The other authors have declared no conflicts of interest. 

Phrase: "The"

Phrase: "other authors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0221193:Authors [Professional or Occupational Group]

Phrase: "have"

Phrase: "declared"

Phrase: "no conflicts of interest."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   966   C0079152:Conflict of Interest [Idea or Concept]
           conflicts interest
   827   C0009671:Conflicts [Individual Behavior]
   827   C0543488:Interest [Mental Process]
   793 E C1705242:Conflict [Qualitative Concept]
Processing 00000000.tx.135: References Watts RA, Scott DGI, Pusey CD, Lockwood CM. 

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Watts RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "Scott DGI,"

Phrase: "Pusey CD,"

Phrase: "Lockwood CM."
Processing 00000000.tx.136: Vasculitis  aims of therapy. 

Phrase: "Vasculitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042384:Vasculitis [Disease or Syndrome]
  1000   C1963274:Vasculitis [Finding]

Phrase: "aims of therapy."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0039798:therapy [Functional Concept]
   790   C0087111:Therapy [Therapeutic or Preventive Procedure]
   790   C1363945:Therapy [Finding]
   790   C1947946:Aim [Idea or Concept]
   790   C2948600:Aim [Pharmacologic Substance]
   790   C3540471:AIM [Gene or Genome]
   790   C3540472:AIM [Functional Concept]
   790   C3540473:AIMS [Intellectual Product]
Processing 00000000.tx.137: Rheumatology 2000;39:22937.[Free FullText] Walton EW. 

Phrase: "Rheumatology 2000"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035452:Rheumatology [Biomedical Occupation or Discipline]
   861   C0334889:Rheumatology [Professional or Occupational Group]

Phrase: ";39"

Phrase: ":"

Phrase: "22937."

Phrase: "[Free FullText"

Phrase: "] Walton EW."
Processing 00000000.tx.138: Giant cell granuloma of the respiratory tract. 

Phrase: "Giant cell granuloma of the respiratory tract."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   814   C0018194:Giant Cell Granuloma [Pathologic Function]
   804   C0018200:Granuloma, Respiratory Tract [Pathologic Function]
   778   C0017526:Giant cell [Cell]
   748   C0007634:Cell [Cell]
   748   C0017547:Giant [Disease or Syndrome]
   748   C0018188:Granuloma [Pathologic Function]
   748   C1269647:Cell [Cell]
   748   C1546654:Granuloma [Intellectual Product]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.139: Br Med J 1958;2:26570.[ISI] Gordon C, Luqmani R, Adu D. 

Phrase: "Br Med J 1958"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1704648:Br. [Conceptual Entity]

Phrase: ";2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ":"

Phrase: "26570."

Phrase: "[ISI] Gordon C,"

Phrase: "Luqmani R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Adu D."
Processing 00000000.tx.140: Relapses in patients with a systemic vasculitis. 

Phrase: "Relapses in patients"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C0035020:Relapses [Phenomenon or Process]
   756 E C0205336:relapse [Temporal Concept]
   756 E C0277556:Relapse [Disease or Syndrome]

Phrase: "with a systemic vasculitis."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0264939:Systemic Vasculitis [Finding]
   861   C0042384:Vasculitis [Disease or Syndrome]
   861   C0205373:Systemic [Functional Concept]
   861   C1963274:Vasculitis [Finding]
Processing 00000000.tx.141: Q J Med 1993;86:77989.[ISI][Medline] de Groot K, Rasmussen N, Cohen-Tervaert JW, Jayne DRW for EUVAS. 

Phrase: "Q J Med 1993"

Phrase: ";86"

Phrase: ":"

Phrase: "77989."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] de Groot K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Rasmussen N,"

Phrase: "Cohen-Tervaert JW,"

Phrase: "Jayne DRW for EUVAS."
Processing 00000000.tx.142: Randomised trial of cyclophosphamide versus methotrexate for induction of remission in non-renal ANCA-associated vasculitis. 

Phrase: "Randomised trial of cyclophosphamide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0008976:Trial [Research Activity]

Phrase: "versus"

Phrase: "methotrexate for induction of remission"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0025677:Methotrexate [Organic Chemical,Pharmacologic Substance]

Phrase: "in non-renal ANCA-associated vasculitis."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   884   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   875   C0152002:Renal vasculitis [Disease or Syndrome]
   804   C0042384:Vasculitis [Disease or Syndrome]
   804   C0103647:ANCA [Immunologic Factor]
   804   C0332281:Associated [Qualitative Concept]
   804   C1963274:Vasculitis [Finding]
   771 E C0750490:Associate [Idea or Concept]
   771 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.143: Arthritis Rheum 2003;48(Suppl):S660.[CrossRef] Jayne D, Rasmussen N, Andrassy K et al. on behalf European Vasculitis Study Group. 

Phrase: "Arthritis Rheum 2003"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0003864:Arthritis [Disease or Syndrome]
   827   C0035431:Rheum [Plant]
   734 E C0018099:Gout [Disease or Syndrome]

Phrase: ";48"

Phrase: "(Suppl):S660."

Phrase: "[CrossRef"

Phrase: "] Jayne D,"

Phrase: "Rasmussen N,"

Phrase: "Andrassy K et al."

Phrase: "on behalf European Vasculitis Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   804   C0441833:Group [Idea or Concept]
   804   C0557651:Study [Manufactured Object]
   804   C0687744:group [Population Group]
   804   C1257890:Group [Population Group]
   804   C1552516:Group [Health Care Related Organization]
   804   C1705428:Group [Conceptual Entity]
   804   C1705429:Group [Population Group]
   804   C2603343:Study [Research Activity]
Processing 00000000.tx.144: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. 

Phrase: "A randomized trial of maintenance therapy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0008976:Trial [Research Activity]

Phrase: "for vasculitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042384:Vasculitis [Disease or Syndrome]
  1000   C1963274:Vasculitis [Finding]

Phrase: "associated with antineutrophil cytoplasmic autoantibodies."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0010834:Cytoplasmic [Cell Component]
   760   C0521449:Cytoplasmic [Body Location or Region]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.145: N Engl J Med 2003;349:3644.[Abstract/Free FullText] Gaskin G, Jayne DR, European Vasculitis Study Group. 

Phrase: "N Engl J Med 2003"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ";349"

Phrase: ":"

Phrase: "3644."

Phrase: "[Abstract/Free FullText"

Phrase: "] Gaskin G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Jayne DR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: "European Vasculitis Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   812   C0441833:Group [Idea or Concept]
   812   C0557651:Study [Manufactured Object]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   812   C2603343:Study [Research Activity]
Processing 00000000.tx.146: Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. 

Phrase: "Adjunctive plasma exchange"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0032113:Plasma Exchange [Therapeutic or Preventive Procedure]
   901   C0032134:Plasma Exchange [Therapeutic or Preventive Procedure]
   827   C0032105:Plasma [Body Substance]
   827   C0678640:exchange [Social Behavior]
   827   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "is"

Phrase: "superior to methylprednisolone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1282910:Superior [Spatial Concept]

Phrase: "in acute renal failure"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0022660:Acute Renal Failure [Disease or Syndrome]
   913   C0231176:Acute failure [Pathologic Function]
   901   C0035078:Renal Failure [Disease or Syndrome]
   901   C1963154:Renal failure [Finding]
   827   C0022646:Renal [Body Part, Organ, or Organ Component]
   827   C0205178:acute [Temporal Concept]
   827   C0231174:Failure [Functional Concept]
   827   C0680095:failure [Individual Behavior]

Phrase: "due to ANCA-associated glomerulonephritis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017658:Glomerulonephritis [Disease or Syndrome]
Processing 00000000.tx.147: J Am Soc Nephrol 2002;13:2A3A. 

Phrase: "J"

Phrase: "Am"

Phrase: "Soc Nephrol 2002"

Phrase: ";13"

Phrase: ":"

Phrase: "2A3A."
Processing 00000000.tx.148: de Groot K, Adu D, Savage COS. 

Phrase: "de Groot K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Adu D,"

Phrase: "Savage COS."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0454802:Cos [Geographic Area]
Processing 00000000.tx.149: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. 

Phrase: "The value of pulse cyclophosphamide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1522609:Value [Quantitative Concept]

Phrase: "in ANCA-associated vasculitis"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   827   C0042384:Vasculitis [Disease or Syndrome]
   827   C0103647:ANCA [Immunologic Factor]
   827   C0332281:Associated [Qualitative Concept]
   827   C1963274:Vasculitis [Finding]
   793 E C0750490:Associate [Idea or Concept]
   793 E C1706221:Associate [Professional or Occupational Group]

Phrase: ":"

Phrase: "meta-analysis"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0282458:Meta-Analysis [Intellectual Product]
  1000   C0920317:Meta-Analysis [Research Activity]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1042496:Meta [Eukaryote]
   861   C1524024:analysis [Functional Concept]

Phrase: "and"

Phrase: "critical review."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0282443:Review [Intellectual Product]
   861   C1552617:Review [Idea or Concept]
Processing 00000000.tx.150: Nephrol Dialysis Transplant 2001;16:201827.[Abstract/Free FullText] Gayraud M, Guillevin L, le Toumelin P, et al. 

Phrase: "Nephrol Dialysis Transplant 2001"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0011945:Dialysis [Natural Phenomenon or Process]
   812   C0011946:dialysis [Therapeutic or Preventive Procedure]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0332835:Transplant [Tissue]
   812   C0917873:dialysis [Therapeutic or Preventive Procedure]
   812   C1059964:Dialysis [Eukaryote]

Phrase: ";16"

Phrase: ":"

Phrase: "201827."

Phrase: "[Abstract/Free FullText"

Phrase: "] Gayraud M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Guillevin L,"

Phrase: "le Toumelin P,"

Phrase: "et al."
Processing 00000000.tx.151: French Vasculitis Study Group. 

Phrase: "French Vasculitis Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   812   C0441833:Group [Idea or Concept]
   812   C0557651:Study [Manufactured Object]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   812   C2603343:Study [Research Activity]
Processing 00000000.tx.152: Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. 

Phrase: "Long-term followup of polyarteritis nodosa,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C1517942:Long-term Follow-up [Health Care Activity]
   753   C0589120:Follow-up [Finding]
   753   C1522577:Followup [Health Care Activity]
   753   C1704685:FOLLOW-UP [Intellectual Product]
   753   C3274571:FOLLOW-UP [Health Care Activity]

Phrase: "microscopic polyangiitis,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0343192:Microscopic Polyangiitis [Disease or Syndrome]
   861   C0205288:Microscopic [Qualitative Concept]
   861   C0264939:Polyangiitis [Finding]
   789 E C0026018:Microscopies [Laboratory Procedure]

Phrase: "and"

Phrase: "Churg-Strauss syndrome"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0008728:Churg-Strauss Syndrome [Disease or Syndrome]
           churg strauss
   827   C0039082:Syndrome [Disease or Syndrome]

Phrase: ":"

Phrase: "analysis of four prospective trials"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "278 patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.153: Arthritis Rheum 2001; 

Phrase: "Arthritis Rheum 2001"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0003864:Arthritis [Disease or Syndrome]
   827   C0035431:Rheum [Plant]
   734 E C0018099:Gout [Disease or Syndrome]

Phrase: ";"
Processing 00000000.tx.154: 44:66675.[CrossRef][ISI][Medline] Edwards JCW, Cambridge G. 

Phrase: "44"

Phrase: ":"

Phrase: "66675."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Edwards JCW,"

Phrase: "Cambridge G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.155: Prospects for B-cell-targeted therapy in autoimmune disease. 

Phrase: "Prospects for B-cell-targeted therapy"

Phrase: "in autoimmune disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0004364:Autoimmune Disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   861   C0443146:Autoimmune [Pathologic Function]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.156: Rheumatology 2005;44:1516.[Free FullText] Edwards JC, Szczepanski L, Szechinski J et al. 

Phrase: "Rheumatology 2005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035452:Rheumatology [Biomedical Occupation or Discipline]
   861   C0334889:Rheumatology [Professional or Occupational Group]

Phrase: ";44"

Phrase: ":"

Phrase: "1516."

Phrase: "[Free FullText"

Phrase: "] Edwards JC,"

Phrase: "Szczepanski L,"

Phrase: "Szechinski J et al."
Processing 00000000.tx.157: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. 

Phrase: "Efficacy of B-cell-targeted therapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280519:Efficacy [Qualitative Concept]
   753   C1707887:EFFICACY [Research Activity]

Phrase: "with rituximab"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0393022:rituximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with rheumatoid arthritis."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0003873:Rheumatoid Arthritis [Disease or Syndrome]
  1000   C2697391:RHEUMATOID ARTHRITIS [Gene or Genome]
   861   C0003864:Arthritis [Disease or Syndrome]
   768 E C0018099:Gout [Disease or Syndrome]
Processing 00000000.tx.158: N Engl J Med 2004;350:257281.[Abstract/Free FullText] Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. 

Phrase: "N Engl J Med 2004"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ";350"

Phrase: ":"

Phrase: "257281."

Phrase: "[Abstract/Free FullText"

Phrase: "] Wegener's Granulomatosis Etanercept Trial"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0008976:Trial [Research Activity]

Phrase: "(WGET"

Phrase: ")"

Phrase: "Research"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0035168:research [Research Activity]
  1000   C0242481:Research [Research Activity]

Phrase: "Group."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0441833:Group [Idea or Concept]
  1000   C0687744:group [Population Group]
  1000   C1257890:Group [Population Group]
  1000   C1552516:Group [Health Care Related Organization]
  1000   C1705428:Group [Conceptual Entity]
  1000   C1705429:Group [Population Group]
Processing 00000000.tx.159: Etanercept plus standard therapy for Wegener's granulomatosis. 

Phrase: "Etanercept plus standard therapy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0717758:Etanercept [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "for Wegener's granulomatosis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0043092:Wegener Granulomatosis [Disease or Syndrome]
   861   C0521173:Granulomatosis [Disease or Syndrome]
Processing 00000000.tx.160: N Engl. 

Phrase: "N Engl."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1414400:ENGL [Gene or Genome]
Processing 00000000.tx.161: J Med 2005;352:35161.[Abstract/Free FullText] Booth A, Harper L, Hammad T et al. 

Phrase: "J Med 2005"

Phrase: ";352"

Phrase: ":"

Phrase: "35161."

Phrase: "[Abstract/Free FullText"

Phrase: "] Booth A,"

Phrase: "Harper L,"

Phrase: "Hammad T et al."
Processing 00000000.tx.162: Prospective study of TNF-alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. 

Phrase: "Prospective study of TNF-alpha blockade"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0033522:prospective study [Research Activity]
   790   C1709709:Prospective Study [Research Activity]
   753   C0023981:prospective [Research Activity]
   753   C0557651:Study [Manufactured Object]
   753   C2603343:Study [Research Activity]

Phrase: "with infliximab"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0666743:infliximab [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   947   C2717865:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis [Disease or Syndrome]
   818   C0264939:Systemic Vasculitis [Finding]
   795   C0042384:Vasculitis [Disease or Syndrome]
   795   C0205373:Systemic [Functional Concept]
   795   C1963274:Vasculitis [Finding]
   710   C0103647:Anti-Neutrophil Cytoplasmic Antibody [Immunologic Factor]
Processing 00000000.tx.163: J Am Soc Nephrol 2004;15: 71721.[Abstract/Free FullText] Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ; 

Phrase: "J"

Phrase: "Am"

Phrase: "Soc Nephrol 2004"

Phrase: ";15"

Phrase: ":"

Phrase: "71721."

Phrase: "[Abstract/Free FullText"

Phrase: "] Schmitt WH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2349143:Wh [Quantitative Concept]

Phrase: "Hagen EC,"

Phrase: "Neumann I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Nowack R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Flores-Suarez LF,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1416933:LF [Gene or Genome]
   827   C2986618:LF [Gene or Genome]

Phrase: "van der Woude FJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0016080:FJ [Geographic Area]

Phrase: ";"
Processing 00000000.tx.164: European Vasculitis Study Group. 

Phrase: "European Vasculitis Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   812   C0441833:Group [Idea or Concept]
   812   C0557651:Study [Manufactured Object]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   812   C2603343:Study [Research Activity]
Processing 00000000.tx.165: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. 

Phrase: "Treatment of refractory Wegener's granulomatosis"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "with antithymocyte globulin (ATG)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003442:Anti-Thymocyte Globulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0017649:Globulin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: ":"

Phrase: "an open study in 15 patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0557651:Study [Manufactured Object]
   753   C2603343:Study [Research Activity]
Processing 00000000.tx.166: Kidney Int 2004; 

Phrase: "Kidney Int 2004"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   827   C0022646:Kidney [Body Part, Organ, or Organ Component]
   827   C0063789:INT [Organic Chemical]
   827   C0227665:kidney [Body Part, Organ, or Organ Component]
   827   C1278978:Kidney [Body Part, Organ, or Organ Component]
   827   C1514845:KIDNEY [Tissue]
   827   C3272375:INT [Intellectual Product]
   734 E C0027697:Nephritides [Disease or Syndrome]

Phrase: ";"
Processing 00000000.tx.167: 65:14408.[CrossRef][ISI][Medline] Williams JM, Kamesh L, Savage CO. 

Phrase: "65"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450385:65 [Intellectual Product]

Phrase: ":"

Phrase: "14408."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Williams JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Kamesh L,"

Phrase: "Savage CO."
Processing 00000000.tx.168: Translating basic science into patient therapy for ANCA-associated small vessel vasculitis. 

Phrase: "Translating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040710:Translating [Occupational Activity]

Phrase: "basic science into patient therapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0681833:Basic Science [Research Activity]
   760   C0036397:Science [Occupation or Discipline]

Phrase: "for ANCA-associated small vessel vasculitis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   911   C2717865:ANCA-Associated Vasculitis [Disease or Syndrome]
   804   C0042384:Vasculitis [Disease or Syndrome]
   804   C1963274:Vasculitis [Finding]
Processing 00000000.tx.169: Clin Sci 2005;108:10112.[CrossRef][ISI][Medline] Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. 

Phrase: "Clin Sci 2005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1315013:CLIN [Intellectual Product]
   827   C3642273:SCI [Professional or Occupational Group]

Phrase: ";108"

Phrase: ":"

Phrase: "10112."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Holland M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Hewins P,"

Phrase: "Goodall M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Adu D,"

Phrase: "Jefferis R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Savage CO."
Processing 00000000.tx.170: Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. 

Phrase: "Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   765   C1275917:Immunoglobulin G subclass [Amino Acid, Peptide, or Protein,Immunologic Factor]
   741   C1302677:Immunoglobulin subclass [Classification]
   739   C0445604:subclasses [Classification]

Phrase: ":"

Phrase: "a possible pathogenic role for the IgG4 subclass."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.171: Clin Exp Immunol 2004;138:18392.[CrossRef][ISI][Medline] van der Geld YM, Stegeman CA, Kallenberg CG. 

Phrase: "Clin Exp Immunol 2004"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C1315013:CLIN [Intellectual Product]
   812   C1417055:EXP [Gene or Genome]
   812   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ";138"

Phrase: ":"

Phrase: "18392."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] van der"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1511780:der [Cell or Molecular Dysfunction]

Phrase: "Geld"

Phrase: "YM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349168:ym [Quantitative Concept]

Phrase: "Stegeman CA,"

Phrase: "Kallenberg CG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]
Processing 00000000.tx.172: B cell epitope specificity in ANCA-associated vasculitis: does it matter? 

Phrase: "B cell epitope specificity in ANCA-associated vasculitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0037791:Specificity [Quantitative Concept]
   744   C1511884:Specificity [Quantitative Concept]

Phrase: ":"

Phrase: "does"

Phrase: "it matter?"
Processing 00000000.tx.173: Clin Exp Immunol 2004;137:4519.[CrossRef][ISI][Medline] Tse W, Nash G, Hewins P, Savage C, Adu D. 

Phrase: "Clin Exp Immunol 2004"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C1315013:CLIN [Intellectual Product]
   812   C1417055:EXP [Gene or Genome]
   812   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ";137"

Phrase: ":"

Phrase: "4519."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Tse W,"

Phrase: "Nash G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Hewins P,"

Phrase: "Savage C,"

Phrase: "Adu D."
Processing 00000000.tx.174: ANCA-induced neutrophil F-actin polymerisation: implications for microvascular inflammation. 

Phrase: "ANCA-induced neutrophil F-actin polymerisation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1155982:actin polymerization [Cell Function]
   799   C0314672:Polymerisation [Phenomenon or Process]

Phrase: ":"

Phrase: "implications for microvascular inflammation."
Processing 00000000.tx.175: Kidney Int 2005;67:1309.[CrossRef][ISI][Medline] Van Rossum AP, Rarok AA, Huitema MG, Fassina G, Limburg PC, Kallenberg CG. 

Phrase: "Kidney Int 2005"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   827   C0022646:Kidney [Body Part, Organ, or Organ Component]
   827   C0063789:INT [Organic Chemical]
   827   C0227665:kidney [Body Part, Organ, or Organ Component]
   827   C1278978:Kidney [Body Part, Organ, or Organ Component]
   827   C1514845:KIDNEY [Tissue]
   827   C3272375:INT [Intellectual Product]
   734 E C0027697:Nephritides [Disease or Syndrome]

Phrase: ";67"

Phrase: ":"

Phrase: "1309."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Van Rossum AP,"

Phrase: "Rarok AA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1235746:Aa [Plant]
   861   C1882141:aa [Qualitative Concept]

Phrase: "Huitema MG,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "Fassina G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Limburg PC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540812:PC [Gene or Genome]

Phrase: "Kallenberg CG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]
Processing 00000000.tx.176: Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. 

Phrase: "Constitutive membrane expression of proteinase 3"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "(PR3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0067033:Proteinase 3 [Amino Acid, Peptide, or Protein,Enzyme,Immunologic Factor]
  1000   C1335267:PROTEINASE 3 [Gene or Genome]
   861   C0030946:Proteinase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C1622131:proteinase [Molecular Function]
   861   C1947941:Proteinase [Enzyme]

Phrase: ")"

Phrase: "and"

Phrase: "neutrophil activation by anti-PR3 antibodies."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0242599:Neutrophil Activation [Physiologic Function]
   757   C1516004:Antibody Activation [Physiologic Function]
   748   C1879547:Activation [Activity]
Processing 00000000.tx.177: J Leukoc Biol 2004;76:116270.[Abstract/Free FullText] Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. 

Phrase: "J Leukoc Biol 2004"

Phrase: ";76"

Phrase: ":"

Phrase: "116270."

Phrase: "[Abstract/Free FullText"

Phrase: "] Calderwood JW,"

Phrase: "Williams JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Morgan MD,"

Phrase: "Nash GB,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0041700:GB [Geographic Area]
   861   C1551090:Gb [Quantitative Concept]

Phrase: "Savage CO."
Processing 00000000.tx.178: ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. 

Phrase: "ANCA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0103647:ANCA [Immunologic Factor]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "beta2 integrin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0064830:beta2 Integrin [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]
  1000   C1334146:INTEGRIN, BETA-2 [Gene or Genome]
   861   C0021701:Integrin [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]
   861   C1417683:BETA2 [Gene or Genome]
   861   C1823554:Beta2 [Gene or Genome]
   861   C3273872:BETA2 [Gene or Genome]

Phrase: "and"

Phrase: "CXC chemokine-dependent neutrophil-endothelial cell interactions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   818   C0007582:Interactions, Cell [Cell Function]
   762   C1704675:Interaction [Functional Concept]

Phrase: "that"

Phrase: "mimic"

Phrase: "those of highly cytokine-activated endothelium."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0014257:Endothelium [Tissue]
   753   C0079189:cytokine [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0205250:Highly [Qualitative Concept]
   753   C1879547:Activated [Activity]
   719 E C1515877:Activate [Functional Concept]
Processing 00000000.tx.179: J Leukoc Biol 2005;77:3343.[Abstract/Free FullText] Harper L, Cockwell P, Adu D, Savage C. 

Phrase: "J Leukoc Biol 2005"

Phrase: ";77"

Phrase: ":"

Phrase: "3343."

Phrase: "[Abstract/Free FullText"

Phrase: "] Harper L,"

Phrase: "Cockwell P,"

Phrase: "Adu D,"

Phrase: "Savage C."
Processing 00000000.tx.180: Neutrophil priming and apoptosis in ANCA-associated vasculitis. 

Phrase: "Neutrophil priming"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0871133:Priming [Functional Concept]

Phrase: "and"

Phrase: "apoptosis in ANCA-associated vasculitis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162638:Apoptosis [Cell Function]
Processing 00000000.tx.181: Kidney Int 2001;59: 172938.[CrossRef][ISI][Medline] Donald KJ, Edwards RL, McEvoy JDS. 

Phrase: "Kidney Int 2001"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   827   C0022646:Kidney [Body Part, Organ, or Organ Component]
   827   C0063789:INT [Organic Chemical]
   827   C0227665:kidney [Body Part, Organ, or Organ Component]
   827   C1278978:Kidney [Body Part, Organ, or Organ Component]
   827   C1514845:KIDNEY [Tissue]
   827   C3272375:INT [Intellectual Product]
   734 E C0027697:Nephritides [Disease or Syndrome]

Phrase: ";59"

Phrase: ":"

Phrase: "172938."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Donald KJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439255:kJ [Quantitative Concept]

Phrase: "Edwards RL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1419337:RL [Gene or Genome]
   861   C3539667:RL [Gene or Genome]

Phrase: "McEvoy JDS."
Processing 00000000.tx.182: An ultrastructural study of the pathogenesis of tissue injury in limited Wegener's granulomatosis. 

Phrase: "An ultrastructural study of the pathogenesis of tissue injury"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0557651:Study [Manufactured Object]
   742   C2603343:Study [Research Activity]

Phrase: "in limited Wegener's granulomatosis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0264994:Limited Wegener's granulomatosis [Neoplastic Process]
   901   C0043092:Wegener Granulomatosis [Disease or Syndrome]
   827   C0521173:Granulomatosis [Disease or Syndrome]
Processing 00000000.tx.183: Pathology 1976;8:1619.[ISI][Medline] Rastaldi M, Ferrario F, Crippa A et al. 

Phrase: "Pathology 1976"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0030664:Pathology [Biomedical Occupation or Discipline]
   861   C0205469:pathology [Functional Concept]
   861   C0677042:pathology [Pathologic Function]
   789 E C1521733:Pathologic [Functional Concept]

Phrase: ";8"

Phrase: ":"

Phrase: "1619."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Rastaldi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Ferrario F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Crippa A et al."
Processing 00000000.tx.184: Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. 

Phrase: "Glomerular monocyte-macrophage"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0024432:macrophage [Cell]

Phrase: "features in ANCA-positive renal vasculitis"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   790   C0152002:Renal vasculitis [Disease or Syndrome]
   790   C0238874:ANCA POSITIVE [Laboratory or Test Result]
   753   C0022646:Renal [Body Part, Organ, or Organ Component]
   753   C0042384:Vasculitis [Disease or Syndrome]
   753   C0103647:ANCA [Immunologic Factor]
   753   C0439178:% Positive [Quantitative Concept]
   753   C1446409:Positive [Qualitative Concept]
   753   C1514241:Positive [Finding]
   753   C1521970:Feature [Qualitative Concept]
   753   C1706388:Feature [Conceptual Entity]
   753   C1963274:Vasculitis [Finding]
   753   C2346469:Feature [Qualitative Concept]
   753   C2348519:Feature [Qualitative Concept]
   753   C2825490:Positive [Qualitative Concept]

Phrase: "and"

Phrase: "cryoglobulinemic nephritis."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0027697:Nephritis [Disease or Syndrome]
   768 E C0022646:Kidney [Body Part, Organ, or Organ Component]
   768 E C0227665:kidney [Body Part, Organ, or Organ Component]
   768 E C1278978:Kidney [Body Part, Organ, or Organ Component]
   768 E C1514845:KIDNEY [Tissue]
Processing 00000000.tx.185: J Am Soc Nephrol 2000;11:203643.[Abstract/Free FullText] Harper L, Ren Y, Savill J, Adu D, Savage C. 

Phrase: "J"

Phrase: "Am"

Phrase: "Soc Nephrol 2000"

Phrase: ";11"

Phrase: ":"

Phrase: "203643."

Phrase: "[Abstract/Free FullText"

Phrase: "] Harper L,"

Phrase: "Ren Y,"

Phrase: "Savill J,"

Phrase: "Adu D,"

Phrase: "Savage C."
Processing 00000000.tx.186: Dysregulated neutrophil apoptosis in systemic vasculitis. 

Phrase: "Dysregulated neutrophil apoptosis in systemic vasculitis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1326212:neutrophil apoptosis [Cell Function]
   753   C0162638:Apoptosis [Cell Function]
Processing 00000000.tx.187: Am J Pathol 2000;157: 21120.[Abstract/Free FullText] Usher LR, Lawson RA, Geary I et al. 

Phrase: "Am"

Phrase: "J Pathol 2000"

Phrase: ";157"

Phrase: ":"

Phrase: "21120."

Phrase: "[Abstract/Free FullText"

Phrase: "] Usher LR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0023617:LR [Geographic Area]
   861   C2986899:LR [Idea or Concept]

Phrase: "Lawson RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "Geary I et al."
Processing 00000000.tx.188: Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. 

Phrase: "Induction of neutrophil apoptosis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   881   C3266896:Induction of Apoptosis [Cell Function]
           Apoptosis Induction
   770   C0205263:Induction [Functional Concept]
   770   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "by the Pseudomonas aeruginosa exotoxin pyocyanin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0034211:Pyocyanin [Biologically Active Substance,Organic Chemical]

Phrase: ":"

Phrase: "a potential mechanism of persistent infection."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0441712:Mechanism [Functional Concept]
   753   C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.189: J Immunol 2002;168: 18618.[Abstract/Free FullText] Brouwer E, Huitema MG, Klok PA, Cohen Tervaert JW, Weening JJ, Kallenberg CGM. 

Phrase: "J Immunol 2002"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ";168"

Phrase: ":"

Phrase: "18618."

Phrase: "[Abstract/Free FullText"

Phrase: "] Brouwer E,"

Phrase: "Huitema MG,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "Klok PA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541314:PA [Idea or Concept]

Phrase: "Cohen Tervaert JW,"

Phrase: "Weening JJ,"

Phrase: "Kallenberg CGM."
Processing 00000000.tx.190: Anti-myeloperoxidase associated proliferative glomerulonephritis: an animal model. 

Phrase: "Anti-myeloperoxidase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]

Phrase: "associated"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332281:Associated [Qualitative Concept]
   966 E C0750490:Associate [Idea or Concept]
   966 E C1706221:Associate [Professional or Occupational Group]

Phrase: "proliferative glomerulonephritis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0235618:Proliferative glomerulonephritis [Disease or Syndrome]
   861   C0017658:Glomerulonephritis [Disease or Syndrome]
   861   C0334094:Proliferative [Pathologic Function]

Phrase: ":"

Phrase: "an animal model."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0599779:Animal Model [Animal]
   861   C0003062:Animal [Animal]
   861   C3161035:Model [Intellectual Product]
Processing 00000000.tx.191: J Exp Med 1993; 

Phrase: "J Exp Med 1993"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1417055:EXP [Gene or Genome]

Phrase: ";"
Processing 00000000.tx.192: 177:90514.[Abstract/Free FullText] Yang JJ, Jennette JC, Falk RJ. 

Phrase: "177"

Phrase: ":"

Phrase: "90514."

Phrase: "[Abstract/Free FullText"

Phrase: "] Yang JJ,"

Phrase: "Jennette JC,"

Phrase: "Falk RJ."
Processing 00000000.tx.193: Immune complex glomerulonephritis is induced in rats immunised with heterologous myeloperoxidase. 

Phrase: "Immune complex glomerulonephritis"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0744421:Immune-complex glomerulonephritis [Disease or Syndrome]
   901   C0003313:Immune complex [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0017658:Glomerulonephritis [Disease or Syndrome]
   827   C0439662:Immune [Functional Concept]
   827   C0439855:Complex [Qualitative Concept]
   827   C1704241:Complex [Chemical Viewed Structurally]

Phrase: "is"

Phrase: "induced in rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0034693:rats [Mammal]
   790   C0034721:Rats [Mammal]
   790   C0205263:Induced [Functional Concept]

Phrase: "immunised with heterologous myeloperoxidase."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0027021:Myeloperoxidase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0439860:Heterologous [Qualitative Concept]
   770   C0440053:Myeloperoxidase [Indicator, Reagent, or Diagnostic Aid]
Processing 00000000.tx.194: Clin Exp Immunol 1994;97:46673.[ISI][Medline] Heeringa P, Brouwer E, Kolk PA et al. 

Phrase: "Clin Exp Immunol 1994"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C1315013:CLIN [Intellectual Product]
   812   C1417055:EXP [Gene or Genome]
   812   C1517844:Immunol [Organic Chemical,Pharmacologic Substance]

Phrase: ";97"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439073:97 [Intellectual Product]
  1000   C0439082:>97 [Quantitative Concept]

Phrase: ":"

Phrase: "46673."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Heeringa P,"

Phrase: "Brouwer E,"

Phrase: "Kolk PA et al."
Processing 00000000.tx.195: Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. 

Phrase: "Autoantibodies to myeloperoxidase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "aggravate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0436331:aggravate [Finding]

Phrase: "mild anti-glomerular-basement-membrane-mediated glomerular injury"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C3263722:Injury [Injury or Poisoning]
   793   C3263723:Injury [Injury or Poisoning]

Phrase: "in the rat."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:Rat, NOS [Mammal]
  1000   C0034721:Rat [Mammal]
Processing 00000000.tx.196: Am J Pathol 1996;149:1695706.[Abstract] Xiao H, Heeringa P, Hu P et al. 

Phrase: "Am"

Phrase: "J Pathol 1996"

Phrase: ";149"

Phrase: ":"

Phrase: "1695706."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Xiao H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Heeringa P,"

Phrase: "Hu P et al."
Processing 00000000.tx.197: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. 

Phrase: "Antineutrophil cytoplasmic autoantibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "specific for myeloperoxidase cause glomerulonephritis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205369:Specific [Qualitative Concept]
   760   C1552740:specific [Intellectual Product]

Phrase: "and"

Phrase: "vasculitis in mice."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0042384:Vasculitis [Disease or Syndrome]
   790   C1963274:Vasculitis [Finding]
Processing 00000000.tx.198: J Clin Invest 2002;110:95563.[Abstract/Free FullText] Lucy CL, Smith J, Cook HT, Haskard DO, Pusey CD. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "2002"

Phrase: ";110"

Phrase: ":"

Phrase: "95563."

Phrase: "[Abstract/Free FullText"

Phrase: "] Lucy CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Smith J,"

Phrase: "Cook HT,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0018510:HT [Geographic Area]
   861   C0677607:HT [Disease or Syndrome]

Phrase: "Haskard"

Phrase: "DO"

Phrase: ","

Phrase: "Pusey CD."
Processing 00000000.tx.199: Immunisation with MPO directly induces small vessel vasculitis with pauci-immune focal segmental glomerulonephritis and alveolar haemorrhage in WKY rats. 

Phrase: "Immunisation with MPO directly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0020971:Immunisation [Therapeutic or Preventive Procedure]
   770   C0042196:immunisation [Therapeutic or Preventive Procedure]
   770   C3244291:immunization [Functional Concept]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "small vessel vasculitis with pauci-immune focal segmental glomerulonephritis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   784   C2717865:Pauci-Immune Vasculitis [Disease or Syndrome]
   742   C0042384:Vasculitis [Disease or Syndrome]
   742   C1963274:Vasculitis [Finding]

Phrase: "and"

Phrase: "alveolar haemorrhage in WKY rats."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0019080:Haemorrhage [Pathologic Function]
Processing 00000000.tx.200: J Am Soc Nephrol 2002; 

Phrase: "J"

Phrase: "Am"

Phrase: "Soc Nephrol 2002"

Phrase: ";"
Processing 00000000.tx.201: 13:170A. 

Phrase: "13"

Phrase: ":"

Phrase: "170A."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1335829:170A [Gene or Genome]
  1000   C1705260:170A [Gene or Genome]
Processing 00000000.tx.202: Little MA, Smyth CL, Ambrose LR, Cook T, Pusey CD. 

Phrase: "Little MA,"

Phrase: "Smyth CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Ambrose LR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0023617:LR [Geographic Area]
   861   C2986899:LR [Idea or Concept]

Phrase: "Cook T,"

Phrase: "Pusey CD."
Processing 00000000.tx.203: In vivo effects of the induction of ANCA on leukocyte adhesion and transmigration as assessed by intravital microscopy. 

Phrase: "In vivo effects of the induction of ANCA"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C1280500:effects [Qualitative Concept]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "on leukocyte adhesion"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1154393:leukocyte adhesion [Cell Function]
   861   C0001511:Adhesion [Pathologic Function]
   861   C0175633:Adhesion [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "transmigration"

Phrase: "as"

Phrase: "assessed by intravital microscopy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0596795:intravital microscopy [Laboratory Procedure]
   770   C0026018:Microscopy [Laboratory Procedure]
   770   C1516048:Assessed [Activity]
Processing 00000000.tx.204: J Am Soc Nephrol 2004;15:693. 

Phrase: "J"

Phrase: "Am"

Phrase: "Soc Nephrol 2004"

Phrase: ";15"

Phrase: ":"

Phrase: "693."
Processing 00000000.tx.205: This Article Full Text (PDF) All Versions of this Article: 44/5/573 most recent keh609v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (2) Disclaimer Request Permissions Google Scholar Articles by Watts, R. 

Phrase: "This Article Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1527021:Text [Intellectual Product]
   827   C1554111:Text [Idea or Concept]
   827   C1705606:Text [Intellectual Product]
   827   C3541382:Text [Intellectual Product]

Phrase: "(PDF)"

Phrase: "All Versions of this Article"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0333052:versions [Functional Concept]
   726 E C2607870:Version [Spatial Concept]

Phrase: ":"

Phrase: "44/5/573 most recent keh609v1"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "when"

Phrase: "this article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "is"

Phrase: "cited"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "if"

Phrase: "a correction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1705565:CORRECTION [Intellectual Product]
  1000   C1947976:Correction [Functional Concept]

Phrase: "is"

Phrase: "posted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0687676:Post [Temporal Concept]
   966   C1704687:Post [Manufactured Object]

Phrase: "Services"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0557854:Services [Occupational Activity]
   966 E C2825316:Service [Manufactured Object]
   966 E C3245478:service [Idea or Concept]

Phrase: "Email"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]

Phrase: "this article to a friend Similar articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1706852:Article [Intellectual Product]

Phrase: "in this journal Similar articles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   896   C0282420:Journal Article [Intellectual Product]
   793   C1706852:Article [Intellectual Product]

Phrase: "in ISI Web"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0282111:Web [Manufactured Object]

Phrase: "of Science Similar articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1706852:Article [Intellectual Product]

Phrase: "in PubMed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1138432:PubMed [Intellectual Product]

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me to new issues of the journal"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0162443:Journal [Intellectual Product,Manufactured Object]
   748   C0205314:New [Temporal Concept]
   714   C0033213:Issue [Finding]
   714   C1706387:Issue [Intellectual Product]

Phrase: "Add to My Personal Archive Download"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0003738:archive [Manufactured Object]
   753   C0024552:MY [Geographic Area]
   753   C1519021:Personal [Organism Attribute]
   753   C1554162:Archive [Idea or Concept]
   753   C1883712:Add [Functional Concept]

Phrase: "to citation manager Search"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1552603:search [Intellectual Product]
   827   C1706202:Search [Activity]

Phrase: "for citing articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1706852:Article [Intellectual Product]

Phrase: "in"

Phrase: ":"

Phrase: "ISI Web of Science"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0282111:Web [Manufactured Object]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "Disclaimer Request Permissions Google Scholar Articles by Watts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   711   C1706852:Article [Intellectual Product]

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.206: Articles by Williams, J. 

Phrase: "Articles by Williams,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "J."
Processing 00000000.tx.207: PubMed PubMed Citation Articles by Watts, R. 

Phrase: "PubMed PubMed Citation Articles by Watts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1706852:Article [Intellectual Product]

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.208: Articles by Williams, J. 

Phrase: "Articles by Williams,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "J."
Processing 00000000.tx.209: Related Collections Other Rheumatology Online ISSN 1462-0332 - Print ISSN 1462-0324 Copyright  2006 British Society for Rheumatology Oxford Journals Oxford University Press Site Map Privacy Policy Frequently Asked Questions Other Oxford University Press sites: Oxford University Press American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics

Phrase: "Related Collections"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0600644:Collections [Intellectual Product]
   861   C1516698:Collection [Functional Concept]
   861   C1704814:Collection [Idea or Concept]
   777 E C1516695:Collected [Idea or Concept]

Phrase: "Other Rheumatology Online ISSN 1462-0332 - Print ISSN 1462-0324 Copyright  2006 British Society"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   786   C0037455:society [Organization]

Phrase: "for Rheumatology Oxford Journals Oxford University Press Site Map Privacy Policy Frequently"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   801   C2735290:Privacy policy [Intellectual Product]
   788   C0242456:Policy [Intellectual Product]

Phrase: "Asked"

Phrase: "Questions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522634:Question [Intellectual Product]

Phrase: "Other Oxford University Press sites"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0205145:Sites [Spatial Concept]
   779 E C1515974:Site [Body Location or Region]
   779 E C2825164:Site [Spatial Concept]

Phrase: ":"

Phrase: "Oxford University Press American National Biography Booksellers' Information Service Children's Fiction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   788   C0887933:fiction [Intellectual Product]

Phrase: "and"

Phrase: "Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary"

Phrase: "of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   852   C0947619:Finger.right [Body Part, Organ, or Organ Component]
   782   C0035621:Rights [Qualitative Concept]
   782   C0205090:Right [Spatial Concept]

Phrase: "and"

Phrase: "Permissions Science School Books Social Sciences Very Short Introductions World's Classics"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   788   C0439658:classics [Qualitative Concept]
   755 E C0439858:Classic [Qualitative Concept]

